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The NDRDI retrospectively recorded from 2004 onwards: 
 ■ deaths in which alcohol was implicated (regardless of history of alcohol dependence); and
 ■ deaths of individuals reported in any of the data sources as having been ‘an alcoholic’ or 
‘alcohol dependent’ or suffering from ‘chronic alcohol use’ or having had a diagnosis of 
‘alcohol dependence syndrome’ (exact terms only) and/or one or more of the relevant 
International Classification of Diseases (ICD) codes (F10.2 to F10.9).
According to the World Health Organization (WHO), alcohol is the eighth leading cause of  
death in the world.3 Most alcohol-attributable deaths are due to injury, cancer, liver cirrhosis  
or cardiovascular disease.
 Poisoning deaths
 Alcohol-related poisonings 
Between 2004 and 2008, 672 poisoning deaths in which alcohol was 
implicated (alone or in conjunction with other drugs) were recorded 
(Table 1). This makes alcohol the drug most frequently implicated in 
all fatal poisonings in Ireland in the five-year period. Most of those 
who died were male. The highest number of deaths was recorded 
in 2007 (170). The median age of those who died of alcohol-
only poisoning was 48 years, that of those who died of alcohol 
polysubstance (alcohol plus other substance/s) poisoning  
was 41 years.
Four of the authors of the report: (l to r) Simone Walsh, 
Marie Sutton, Suzi Lyons and Ena Lynn
On 12 July the third publication 
from the National Drug-Related 
Deaths Index (NDRDI) was 
launched.1 HRB Trends Series 
10 describes, for the first time, 
trends in alcohol-related deaths  
and deaths among people 
who were alcohol dependent 
in Ireland for the years 
2004−2008. 
The NDRDI was established in 
September 2005 as a system 
for recording drug-related 
deaths and deaths among drug 
users;2 its remit was expanded 
in January 2006 to include 
alcohol-related poisonings and 
deaths among people who were 
alcohol dependent. 
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Alcohol-related>deaths>(continued)
Table 1 Alcohol-related poisoning deaths (NDRDI 2004–2008) (N = 671)
2004 2005 2006 2007 2008
Total 125 116 111 170 150
Alcohol only (n = 331) 61 51 54 85 80
Alcohol polysubstance (n = 341) 64 65 57 85 70
Just over half (50.7%) of all alcohol-related poisonings involved another substance. Most commonly 
implicated along with alcohol were benzodiazepines (61.3%) and opiates (including heroin and 
methadone) (55.7%) (Table 2).
Table 2 Additional drugs involved in alcohol polysubstance poisoning deaths (NDRDI  
2004–2008) (N = 341)
%
All alcohol polysubstance poisonings* 100.0
Benzodiazepines 61.3
Antidepressants 23.5
Heroin 22.9
Other opiates 21.4
Other prescription medication 15.5
Methadone 11.4
Cocaine 9.1
Other‡ 8.8
* Percentages in columns do not add up to totals shown in this row because individual deaths 
may be attributable to more than one drug or substance. 
† Excludes heroin and methadone.
‡ Includes other illicit and licit drugs such as amphetamines, hallucinogens, volatile inhalants, 
cannabis or non-opiate analgesia.
All NDRDI-recorded poisoning deaths 
Table 3 presents data on alcohol poisonings alongside data on poisonings from all other substances in 
order to compare the contribution of alcohol to fatal poisonings nationally. Alcohol was implicated in 
40.7% of all poisonings, making it the drug most frequently implicated in fatal poisonings in Ireland 
for the period 2004–2008. 
Table 3 Drugs involved in all poisoning deaths in Ireland (NDRDI 2004–2008) (N=1,650)
%
All poisoning deaths* 100.0
Alcohol 40.7
Benzodiazepines 31.1
Heroin 18.7
Methadone 16.7
Antidepressants 16.7
Other prescription drugs 14.5
Cocaine 14.0
Other opiates† 17.3
Non-opiate analgesic 5.0
MDMA 3.3
Other‡ 3.1
* Percentages in column do not add up to total shown in this row because individual deaths  
may be attributable to more than one drug or substance.
† Excludes heroin and methadone.
‡ Includes other illicit and licit drugs such as amphetamines, hallucinogens, volatile inhalants  
or cannabis.
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3Non-poisoning deaths in those who were alcohol dependent
There were 3,336 non-poisoning deaths of people who were alcohol dependent, increasing from 508 in 2004 to 799 in 2008 
(Table 4). Almost all (89.2%) were due to medical causes, the remainder (10.8%) were due to traumatic causes.
Table 4 Causes of death in people who were alcohol dependent (NDRDI 2004–2008) (N = 3,336)
2004 2005 2006 2007 2008
Total 508 564 720 745 799
Medical (n = 2,975) 459 499 617 680 720
Trauma (n = 361) 49 65 103 65 79
Alcohol-related>deaths>(continued)
The NDRDI assigns medical and traumatic causes of death to 
a limited number of broad categories to allow for data to be 
presented in a meaningful way. 
Examples of medical-cause categories:
•	 Haemorrhage includes deaths due to ruptured 
oesophageal varices, gastrointestinal bleed (but not 
cerebral haemorrhage);
•	 Cerebral includes deaths as a result of a stroke, 
cerebral haemorrhage (non-traumatic);
•	 Other respiratory disease includes emphysema, 
chronic obstructive airways disease;
•	 Other infection includes sepsis or peritonitis.
Examples of traumatic-cause categories:
•	 Fall includes deaths as a result of a fall from a height 
(from a building or down a stairs) or fall on same 
level (trip over step or from footpath)
•	 Choking includes deaths as a result of asphyxia due 
to foreign body (for example food or vomit);
•	 Violence includes fatal injuries as a result of an 
assault, shooting or stabbing;
•	 Road traffic collision (RTC) includes drivers (of any 
vehicle), passengers or pedestrians.
Deaths from medical causes
The number of deaths from medical causes in people who 
were alcohol dependent rose from 459 in 2004 to 720 in 
2008. Half were aged 59 years or under and the highest 
number of cases was in the 55–59-year age group (15.7%). 
Seventy-four per cent were male. The most frequent causes 
of death in this group were: alcoholic liver disease (23.6%); 
cardiac conditions (17.2%); and respiratory infections 
(11.4%).
Deaths from traumatic causes
The number of deaths as a result of a traumatic event was 
highest in 2006 (103 deaths). Half were aged 49 years or 
under. The most frequent causes of death in this group 
were: falls (39.9%); hanging (19.4%); and choking (12.2%). 
Deaths from medical or traumatic causes that also 
involved alcohol, of people who were not alcohol 
dependent
A further 215 non-poisoning deaths in which alcohol was 
implicated were recorded among people who did not have 
a recorded history of alcohol dependence. The number of 
these deaths increased from 14 in 2004 to 84 in 2008. 
The majority (66.0%) died as a result of traumatic events, 
most commonly drowning (21.1%) and choking (18.3%).
Conclusion
The increase in the number of deaths recorded may be 
explained by a number of factors. It could indicate a true 
increase in the number of deaths, or an effect of improved 
recording practices, as the NDRDI is a relatively new system. 
However, given that the per capita consumption of alcohol 
in Ireland is among the highest in Europe,4 and that 56% of 
Irish people drink in a harmful manner,5 a combination of 
these factors is the most likely explanation.
Alcohol was the drug most frequently implicated in all fatal 
poisonings in Ireland in the five-year period. The findings of 
this analysis in relation to the types of non-poisoning death 
in which alcohol was implicated are similar to those of other 
international research on alcohol-attributable mortality. 
However, the NDRDI data will need to be further analysed  
in detail to better understand the relationship between 
alcohol use and specific diseases, for example breast or 
oesophageal cancer.
The analysis showed clearly the extent of premature 
mortality as many of those who died were still in their prime, 
aged between 40 and 59 years. The NDRDI will be able to 
measure the effects of any changes in public health policy on 
alcohol-related mortality in the Irish population.
(Suzi Lyons)
1. Lyons S, Lynn E, Walsh S, Sutton M and Long J (2011) 
Alcohol-related deaths and deaths among people who were 
alcohol dependent in Ireland, 2004 to 2008. HRB Trends 
Series 10. Dublin: Health Research Board.  
www.drugsandalcohol.ie/15370
2. Lyons S, Lynn E, Walsh S and Long J (2008) Trends 
in drug-related deaths and deaths among drug users in 
Ireland, 1998 to 2005. HRB Trends Series 4. Dublin: 
Health Research Board. www.drugsandalcohol.ie/11513
3. World Health Organization (2011) Global status report on 
alcohol and health. Geneva: World Health Organization. 
www.who.int/substance_abuse/en
4. OECD (2010) OECD health data 2010 - frequently 
requested data. Accessed May 2011 at  
www.oecd.org/dataoecd/52/42/48304068.xls
5. Morgan K, McGee H, Watson D, Perry I, Barry M, Shelley 
E et al. (2008) SLÁN 2007: survey of lifestyle, attitudes and 
nutrition in Ireland. Main report. Dublin: Department of 
Health and Children.  
www.dohc.ie/publications/slan07_report.html
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methodologies
Report on incidence of alcohol-related 
brain injury
Although population surveys which focus on alcohol 
consumption and alcohol-related harm are regularly 
conducted in most European countries, comparison 
of results across countries is difficult due to the lack of 
standardised methodologies. The SMART (Standardising 
Measurement of Alcohol-Related Troubles) project team 
was established to develop a standardised comparative 
survey methodology on alcohol consumption, alcohol-
related problems and public support for policy measures. 
Ten European countries, including Ireland, were involved in 
developing these guidelines.1
Following a literature review on methodologies of alcohol 
surveys and a number of expert meetings, a survey protocol 
for a comparative drinking survey was designed, which was 
then piloted in the participating countries. The proposed 
questionnaire had a number of core sections, each with 
guidelines for its implementation. It is estimated that an 
interview based on these core questions should not last 
longer than 10–15 minutes, especially if CAPI (Computer 
Assisted Personal Interview) is used. 
1. Alcohol consumption: frequency, beverage-specific 
quantity and frequency, and context of drinking;
2. Risky single-occasion drinking and drunkenness;
3. Adverse consequences of own alcohol use;
4. Rapid alcohol problem screen;
5. Unrecorded alcohol supply;
6. Harm from others; and
7. Attitudes towards alcohol policy.
The results of the pilot study demonstrated that comparative 
alcohol surveys are feasible across Europe despite the 
existence of different drinking cultures, various political 
traditions and economic inequalities. While there is a need to 
confirm the results of the pilot test in larger, random samples 
of inhabitants of different European countries, ‘it is expected 
that better use of standardized approaches across Europe will 
lead to more informed and evidence based policy making to 
reduce alcohol’s health and economic burden’. 
(Deirdre Mongan)
1. Moskalewicz J and Sieroslawski J (2010) Drinking 
population surveys: guidance document for standardized 
approach. Warsaw: Institute of Psychiatry and Neurology. 
http://www.drugsandalcohol.ie/15682/
Alcohol-related brain injury (ARBI) is a term used to describe 
physical impairment to the brain sustained as a result of 
alcohol consumption. The two most common conditions 
associated with ARBI are: Wernicke’s encephalopathy, an 
acute condition caused by a lack of thiamine and which 
causes confusion, ataxia and disturbance of the muscles 
controlling eye movement; and Korsakoff’s amnesic 
syndrome, a chronic condition that leads to difficulty in 
learning new information, memory loss and confabulation. 
Other associated conditions include cerebellar atrophy, 
peripheral neuropathy, hepatic encephalopathy and frontal 
lobe dysfunction. 
The North West Alcohol Forum (NWAF) recently published 
the results of research they commissioned in relation to ARBI 
in three counties in the Health Service Executive (HSE) West 
Region (Donegal, Sligo and Leitrim) and the Western Health 
and Social Care Trust (WHSCT) area in Northern Ireland.1
Data from all acute hospitals in both areas for 2005–2009 
were obtained to determine the incidence of ARBI. 
There were 163 ARBI admissions to acute hospitals in the 
three HSE West counties and 151 in the WHSCT area in that 
period. The report does not give population rates. In both 
areas the majority of admissions were male (68% in the  
HSE West and 62% in the WHSCT area) and were aged  
over 55 years. 
A number of interviews were conducted with health 
professionals who highlighted the difficulties in obtaining 
accurate data on the incidence of ARBI and the potential for 
under-reporting. They also stated that there are currently no 
defined care pathways for people with ARBI in either area. 
As a result, ‘people with a high level of care needs may be 
placed in inappropriate care settings such as older people’s 
homes or dementia care settings’. 
The authors conclude that there is anecdotal evidence 
that the prevalence of ARBI is growing but that there is no 
systematic way of capturing data conclusively; that there 
is no co-ordinated approach to treating patients with ARBI 
due to the absence of a clear pathway of care; and that ‘the 
lack of agreement as to whether ARBI is considered a mental 
health condition or a brain injury results in a dilemma as to 
which pathway of care the patient should follow’. 
(Deirdre Mongan)
1. North West Alcohol Forum (2011) Assessment of 
incidences of alcohol-related brain injury (ARBI) in the HSE 
West (Donegal, Sligo, Leitrim) and Western Health and 
Social Care Trust areas. Donegal: North West Alcohol 
Forum. http://www.drugsandalcohol.ie/15440/
drugnet>
Ireland
5Cost of alcohol-attributable 
hospitalisations in Ireland
Harmful use of alcohol can result  
in substantial economic costs
Harmful use of alcohol is a considerable burden on Irish 
hospitals. A recent Irish study calculated the number and 
costs of hospital bed days due wholly or partially to alcohol 
use over the five-year period 2000 to 2004.1 Research by the 
Health Research Board has established that conditions wholly 
attributable to alcohol accounted for 3.6% of all bed days 
in Ireland in 2008.2 However, this analysis did not reflect the 
hospitalisations due to alcohol across all injury and disease 
categories known to be causally related to alcohol. 
Age- and sex-specific alcohol-attributable-fractions (AAFs) 
for Ireland were developed by combining international risk 
estimates with Irish consumption data where available; 
where Irish AAFs were not available, international AAFs 
were used. These were applied to two national datasets 
– the Hospital In-Patient Enquiry Scheme (HIPE) and the 
National Psychiatric In-patient Reporting System (NPIRS) – to 
calculate the number and costs of bed days wholly caused 
and prevented by alcohol, and that proportion of bed days 
that were partially caused and prevented by alcohol. 
Between 2000 and 2004, alcohol was estimated to have 
caused 3,428,973 (10.3%) and prevented 529,239 (1.6%) 
of hospital bed days, giving a net number of bed days due 
to alcohol of 2,899,734 (8.7%). Bed days wholly attributable 
to alcohol accounted for only 33% of all alcohol-attributable 
bed days. The impact of alcohol on hospital bed days was 
greater in men than in women and greater in young to 
middle aged people than older people, which supports 
previous Irish and international findings. The effect of low 
levels of alcohol consumption, which can protect against 
cardiovascular disease, on hospitalisations was seen only in 
the older age groups of both sexes. Alcohol did not prevent 
bed days among the younger age groups.
Ninety-five per cent (n=3,262,408) of bed days attributed 
to the harmful effects of alcohol were due to chronic 
conditions associated with alcohol, and 5% were due 
to acute conditions. Cardiovascular and cerebrovascular 
diseases accounted for 48% of bed days due to alcohol and 
neuropsychiatric diseases accounted for 36%. Conditions not 
wholly due to alcohol accounted for two thirds (2,297,412) 
of hospital bed days due to the harmful effects of alcohol. 
The hospital inpatient cost attributed to the negative effects 
of alcohol was €953,126,381 and the cost saved from 
prevented hospitalisations was €147,968,164, giving a net 
cost of €805,158,217. 
The negative impacts of alcohol were greater than previously 
thought and spread across the whole population. As this 
analysis does not include the costs associated with patients 
attending GPs, outpatient services, emergency departments 
and private hospitals, the costs presented here represent 
only a portion of total hospital costs and a small portion 
of total healthcare costs. However, even this conservative 
estimate of cost is considerable and indicates a significant 
preventable burden on our health care system. 
(Deirdre Mongan)
1. Martin J, Barry J and Skally M (2011) Alcohol attributable 
hospitalisations and costs in Ireland, 2000–2004.  
Irish Medical Journal, 104(6): 140–4.  
www.drugsandalcohol.ie/15284
2. Mongan D (2010) The burden of alcohol-related 
morbidity on hospital services. Drugnet Ireland, 
(35): 9–12.  
www.drugsandalcohol.ie/13967 
A report by Byrne1 aimed to calculate the quantifiable costs 
imposed on Irish society in 2007 by harmful use of alcohol. 
These cost estimates can assist policy makers in justifying 
and evaluating policies, such as taxation measures, that 
are aimed at reducing alcohol-related harm, and can help 
to identify research needs and gaps in national statistical 
reporting systems. Cross-national comparisons of cost 
estimates are useful in assessing the negative consequences 
of alcohol use in different countries and the different policy 
approaches to dealing with these consequences. 
The costs associated with harmful use of alcohol include 
both the private cost incurred by the drinker, such as 
medical expenses, and external costs which are borne by 
third parties. The taxpayer bears significant external costs in 
the form of increased healthcare costs and the cost to the 
justice system of dealing with alcohol-related crime. The 
methodology used by the author of this study to estimate 
the cost of harmful use of alcohol was based on the methods 
used in similar reports from other developed countries, 
including the UK, and used data from surveys  
and surveillance systems.
In 2007 the overall cost of harmful use of alcohol in Ireland 
was estimated to be €3.7 billion, representing 1.9% of 
GNP that year. The overall economic cost as a percentage 
of GNP was broadly in line with estimates calculated for 
other EU countries. A breakdown of these costs is presented 
in Table 1. Health system costs accounted for 32% of the 
overall cost, and included the costs of general practitioner 
and community care (€574 million), hospital inpatient 
care (€500 million), and mental health services (€104 
million). Alcohol-related crime also accounted for 32% of the 
overall cost, and included the costs of property, health and 
victim services (€435 million), the criminal justice system 
(€319 million), security systems (€264 million) and loss of 
productive output (€171 million).
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problem alcohol use in illicit drug users
Costs>of>harmful>use>of>alcohol>(continued)
Table 1 Overall cost of harmful use of alcohol in Ireland 
in 2007
Alcohol-related 
events
€ million % of total 
cost
Illness 1,200 32
Crime 1,189 32
Road accidents 526 14
Absence from work 330 9
Accidents at work 197 5
Suicides 167 5
Premature mortality 110 3
Total 3,710 100
Source: After Byrne (2011), p. 32
These estimates include only the tangible costs of harmful 
use of alcohol and are an underestimate of the total costs 
insofar as sufficient data are not available in Ireland to 
calculate some of the intangible costs included in estimates 
from other countries. Intangible costs include the pain and 
suffering caused to both the drinker and those affected 
by his/her behaviour. No attempt is made in this report 
to calculate these human or emotional costs. When the 
unquantified human costs are considered, estimates of the 
tangible costs greatly understate the true cost to society of 
harmful use of alcohol. 
(Deirdre Mongan)
1. Byrne S (2011) Costs to society of problem alcohol use in 
Ireland. Dublin: Health Service Executive.  
www.drugsandalcohol.ie/15781
The Health Research Board (HRB) has awarded a fellowship 
to complete a Cochrane review entitled ‘Psychosocial 
interventions for problem alcohol use in illicit drug users’ 
to a team based in the University of Limerick. The review 
aims to find out whether interventions that are based on 
behavioural, motivational or social theories of change for 
treating alcohol problems could also be effective for people 
with coexisting addiction issues. 
The findings of the review will inform the development of 
clinical guidelines for screening and treatment for problem 
alcohol use among methadone users attending Irish primary 
care services.1
Cochrane fellowships aim to build capacity in conducting 
systematic reviews in the health and social care field in 
Ireland by freeing up protected time for applicants to 
conduct a review.2 The Cochrane Collaboration is a not-
for-profit independent organisation dedicated to providing 
readily available, up-to-date, accurate information on 
the effects of healthcare interventions. It produces and 
disseminates systematic reviews of healthcare interventions 
in over fifty topic areas through The Cochrane Library (www.
thecochranelibrary.com). In 2002 Ireland became the first 
country in the world to provide free national access to the 
Cochrane Library, an initiative co-funded by the HRB and the 
Research and Development Office in Northern Ireland. 
The co-reviewers are Dr Jan Klimas, Prof Walter Cullen, 
Prof Clodagh O’Gorman, Dr Jean Saunders and Prof 
Colum Dunne (all Graduate Entry Medical School, UL); Ms 
Catherine-Anne Field and Prof Gerard Bury (UCD School 
of Medicine and Medical Science); Dr Eamon Keenan (HSE 
Addiction Services, Dublin) and Dr Liam Glynn (NUIG School 
of Medicine) who is acting as a local mentor on this review. 
More information about the project is available from Jan 
Klimas (01– 473 0893) or from the Cochrane Library, where 
the protocol for this review was published in August.3
(Jan Klimas)
1. Lyons S (2011) Problematic alcohol use among 
methadone users: update on a HRB-funded study. 
Drugnet Ireland (37): 18–19.  
www.drugsandalcohol.ie/14999
2. For more information about the Cochrane Fellowships 
visit: http://www.hrb.ie/research-strategy-funding
3. Klimas J, Field CA, Cullen W, O’Gorman CSM, Glynn 
LG, Keenan E et al. (2011) Psychosocial interventions 
for problem alcohol use in illicit drug users. Cochrane 
Database of Systematic Reviews 2011, Issue 8.  
Art. No.: CD009269.  
www.mrw.interscience.wiley.com/cochrane.
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This section contains short summaries of recent reports and 
other developments of interest.
Coolmine Therapeutic Community (CTC) longitudinal study
In August 2010 CTC started a longitudinal research study in 
collaboration with Paula Mayock of Trinity College Dublin 
and the National Health Information Systems Unit of the 
Health Research Board. 
The aims of the study are to:
•	 collect baseline data on drug use, health and behavioural 
status of participants as they enter and progress through 
primary treatment and aftercare in CTC;
•	 follow up participants over time including after 
leaving the CTC programme; and 
•	 compare CTC client outcomes with outcomes 
recorded in other national studies, e.g. ROSIE.
The study will use both quantitative and qualitative 
methodologies and it is estimated that up to 30 people will 
participate. Participant’s progress will be followed up every 
six months during their treatment (i.e. three times) and 
then 18 months after discharge. The quantitative data will 
be obtained using the Treatment Outcomes Profile tool and 
routine data collected through the National Drug Treatment 
Reporting System. The qualitative data, collected through 
one-to-one interviews with participants, will help reveal their 
reasons for choosing treatment in a therapeutic community 
and their perceived progress over time. The experiences of 
those who drop out of the programme will also be recorded 
and analysed. 
Prevalence of adult ADHD in psychiatric clinic in north Dublin
Syed and colleagues1 estimated the prevalence of attention-
deficit hyperactivity disorder (ADHD) in adults attending 
outpatient psychiatric services. A total of 265 adults (aged 
18–65) attending six out-patient clinics in north Dublin 
were asked to complete the World Health Organization 
Adult ADHD Self-Report Scale VI.I questionnaire; 243 (92%) 
did so. Respondents rated themselves against six criteria 
(a symptom checklist) on a five-point scale. Demographic 
and clinical data were also recorded using a self-completed 
questionnaire and the medical record. 
The average age of the respondents was 42.5 years and 56% 
were women. Using the WHO scale, 24% were diagnosed as 
having ADHD. Of the ADHD cases, 69% were men and the 
average age was 42.1 years. Almost 11% had a diagnosis 
of substance misuse (alcohol and other drugs). When 
compared to patients without ADHD, those diagnosed with 
ADHD were significantly more likely not to have completed 
second-level education, to have had an ADHD diagnosis or 
ADHD symptoms in childhood, to have a forensic history, a 
current personality disorder diagnosis and a higher rate of 
prescribed benzodiazepine use. The data indicate that ADHD 
is common among adults treated for mental illness. None 
of the patients had a recorded diagnosis of adult ADHD, 
indicating significant under-diagnosis of this manageable 
condition. 
DAA launches information guide and new website
On June 15, Irish AIDS Day, the Minister of State at the 
Department of Health, Róisín Shortall TD, launched the 
Dublin Aids Alliance (DAA) information booklet, Living with 
HIV in Ireland: a self-help guide, and the new DAA website 
www.dublinaidsalliance.ie. The guide was developed in 
response to needs identified in the course of many years 
of community support work and through focus groups 
involving HIV positive people and various stakeholders.  
The new website provides a lot of relevant information, 
including where to access services. DAA hopes that it will 
increase sexual health awareness among the general public. 
DAA Executive Director Anna Quigley acknowledged the 
positive impact the work of its partners in the statutory, 
community and voluntary sectors was having in reducing 
the number of newly reported infections. However, she 
cautioned that more needed to be done to raise awareness 
as HIV is a preventable disease. The DAA recommends that a 
national strategy on sexual health be developed to provide a 
co-ordinated approach to this problem. 
Evaluation of self-harm awareness training programme
The National Suicide Research Foundation evaluated the 
self-harm awareness training programme currently delivered 
throughout HSE South and HSE West.2
The study aimed to identify whether the training changed 
participants’ knowledge, attitudes and confidence in relation 
to people who self-harm. The objective was then to identify 
the resources required and the indicators of, and barriers 
to, the successful implementation of the training. Of 532 
participants who completed the programme, 120 returned 
a completed self-report questionnaire. The study revealed 
significant positive changes post training in terms of increased 
knowledge, enhanced positive attitudes towards and 
confidence in dealing with people who engage in self-harm.
Drug Treatment Court
In late July 2011 the Courts Service and the Health Service 
Executive agreed to extend the catchment area of the DTC 
to all areas of Dublin county north of the river Liffey, and 
to make the Court accessible to those receiving treatment 
in the Castle Street Drug Treatment Centre, which provides 
services to people in Dublin 2,4,6 and 8. The extension 
of the catchment area will be piloted for a period of six 
months, after which the capacity of the court to manage a 
further extension will be considered. Courts Service press 
release: www.drugsandalcohol.ie/15689
White Paper on crime
The Department of Justice and Law Reform has published 
the fourth and final document as part of a consultation 
process to develop a White Paper on crime. The White 
Paper, due to be completed in 2011, will provide a high-
level statement of government policy, its rationale and the 
strategies to give effect to that policy. The four thematic 
discussion documents are available at  
www.justice.ie/en/JELR/Pages/White_Paper_on_Crime
(Contributors Suzi Lyons, Jean Long, Vivion McGuire, Fiona 
Bannon and Johnny Connolly)
1. Syed H, Masaud TM, Nkire N, Iro C and Garland MR 
(2010) Estimating the prevalence of adult ADHD in 
the psychiatric clinic: a cross-sectional study using the 
adult ADHD self-report scale (ASRS). Irish Journal of 
Psychological Medicine, 27(4): 195-197.
2. Arensman E and Coffey C (2010) The efficacy of a 
self-harm awareness training programme: report of an 
independent evaluation. Cork: National Suicide Research 
Foundation. www.nosp.ie/html/reports.html
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8Merging policies on psychoactive 
substances
In 2007 the Council of Europe’s Pompidou Group (PG), 
whose core mission is to contribute to the development of 
effective and evidence-based drug policies in member states, 
started an enquiry into how policy on different psychoactive 
drugs is organised in different countries. The PG has now 
published two reports on its investigation and is embarking 
on a third phase. Ireland is one of seven countries that the 
Pompidou Group is studying in depth. 
The first phase of the investigation revealed that policies on 
psychoactive substances in 17 Council of Europe member 
states lay along a continuum between an integrated 
substance-use policy at one end and separate policies for 
different substances at the other end.1 Ireland was found to 
lie near the midway point, with three separate policies for 
illicit drugs, alcohol and tobacco, but a tendency to combine 
elements of illicit drugs and alcohol policy and practice.2
This preliminary investigation led to two recommendations 
– (1) develop a global policy framework for psychoactive 
substances within the context of health, and (2) improve 
the use of research evidence in policy making.2 These 
conclusions influenced the direction and shape of the  
second phase of the PG’s enquiry, the results of which  
were published in November 2010 and are briefly  
outlined below.3
Evidence from ‘social cognitive neural science’ 
In the first part of the new report, Richard Muscat, professor 
of behavioural neuroscience at the University of Malta, reviews 
the contribution of scientific evidence to policy making. 
Having outlined how epidemiological research over several 
decades has helped to determine the size of the problem 
associated with the use of psychoactive substances and its 
impact on society, he describes how biomedical research, 
including the emerging discipline of social cognitive neural 
science,4 is now improving our understanding of why people 
use psychoactive substances, why some users go on to 
become addicted/dependent, and how this new research 
evidence could help to improve the efficacy of policy making 
in the area of psychoactive substances. 
Muscat describes the research evidence for how individual 
substances, including alcohol, tobacco, marihuana, 
cocaine, amphetamines, ecstasy, heroin, methadone 
and buprenorphine, affect the functioning of the brain 
and the consequences for the brain’s reward system 
(which influences behaviour), learning and memory, and 
decision making. He goes on to discuss the evidence for 
how addiction/dependence develops, looking at recent 
research on the contribution of neural processes, psychiatric 
disorders, genetic predisposition, psychological traits and 
sociological determinants. 
Providing clearer insights into what determines our health 
and well-being, social cognitive neural science can, Muscat 
suggests, significantly improve policy making in the area 
of prevention, harm reduction and treatment for problems 
associated with a wide range of psychoactive substances. For 
example, a prevention campaign could target youngsters 
with specific psychological traits such as sensation seeking, 
which guides their decision making. With regard to harm 
reduction, Muscat observes that policy interventions are 
only adopted at national level after the measures have been 
found to work on the ground; he suggests that this pattern 
should be reversed ‘because policy makers should take 
cognisance of current scientific evidence earlier on’. 
‘Integrating’ policies on psychoactive substances
In the second part of the report, Dike van de Mheen and 
Cas Barendregt of the Addiction Research Institute in the 
Netherlands report on an empirical investigation into (1) 
what the term ‘integrated policy’ means in seven countries 
chosen for study, including Ireland, and (2) how ‘integrated 
policy’ has been operationalised in these countries. A ‘short 
open questionnaire’ to elicit information on these two 
research questions was sent to one or two national experts 
in each country for completion, and was followed up by 
telephone interviews with the national experts. 
A key finding is that the concept of ‘integration’ is highly 
nuanced. In order to ensure effective policy structures, 
it is essential to understand the nuances. To begin with, 
integration may refer to the combination of a variety of 
psychoactive substances in the one substance misuse policy. 
Alternatively, it may refer to the co-ordination of policies 
and actions in different government departments through a 
formal co-ordinating mechanism. Ireland is unique among 
the seven countries investigated as part of the study in 
having separate policies on drugs, alcohol and tobacco and 
not having any formal integrated structure for co-ordinating 
policies on psychoactive substances (Figure 1). 
Underlying these two structural forms of integration is the 
possible integration of ideas (politics) and action (policy). 
The authors explain: 
If the idea is that the consumption of psychoactive 
substances, other than tobacco or alcohol, is sinful or 
bad it may lead to prohibition of these substances. If 
the dominant idea is that legal and illegal substances 
can be viewed as potentially damaging to health, 
a health approach to psychoactive substances 
comes into focus. Co-ordination of health-oriented 
interventions requires a different policy infrastructure 
from a merely prohibitionist approach. (p. 57).
Figure 1 Two dimensions of integration: 
substances and co-ordination
Source: After Muscat et al. (2010), p. 55
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9Report on new psychoactive substances 
and the outlets supplying them
The NACD commissioned a study of new psychoactive 
substances and the outlets supplying them, which was 
completed by  
a research team from the Dublin Institute  
of Technology (DIT) and published in  
June 2011.1 
The study comprised several components:
•	 Chemical analysis of 49 new psychoactive substances 
sold in head shops or online
•	 Review of the availability of head shop products in 
retail outlets and via online sales
•	 Users’ reported use and effects of such substances 
•	 Risks associated with the use of such substances 
•	 Legal responses to control the availability of such 
substances.
Analyses of the products bought in head shops and online 
detected the emergence of five new substances following 
the changes introduced by the Misuse of Drugs Act 1977 
(Controlled Drugs) (Declaration) Order of May 2010, 
namely: dimethylcathinone, naphyrone, fluorotropacocaine, 
desoxypipradol and dimethylamylamine. ‘A comparison of 
substances identified before and after the May 2010 Order 
indicates that suppliers moved quickly to replace controlled 
substances with new uncontrolled substances’ (p.74). Five 
products bought online as part of the study all contained 
controlled substances, including mephedrone. This led 
the authors to conclude that ‘head shops may respond 
to local control measures more quickly than international 
online suppliers’ (p.74). The analysis also found a lack of 
consistency between the advertised content and the actual 
content of products, and, over time, between products with 
the same name or packaging. These findings, according to 
the authors, ‘have implications for consumers, including 
the potential for misuse, adverse reactions and possible 
overdose’ (p.74).
The authors observe that as a consequence of the May 2010 
Order and the Criminal Justice (Psychoactive Substances) 
Act 2010 which came into effect on 23 August 2010, the 
vast majority of head shops had closed. Ten to twelve 
remained opened in November 2010, ‘selling pipes, bongs 
and clothing. None are selling psychoactive substances and 
only one…was observed to have hydroponic equipment on 
display’ (p.75).
The authors did an anonymous online survey, using 
a self-completed questionnaire, to identify what 
new psychoactive substances were used, how and 
in what contexts they were used and what effects 
were experienced. The questionnaire had 51 items 
covering demographics, alcohol and tobacco use, use 
of powders, party pills, liquid highs, smoking blends 
and ethnobotanicals. Participants were recruited over 
a two-week period through print and online media, 
personal contacts and DIT staff and student listings. 
Of the 333 survey entries completed, four were 
excluded as invalid. The authors stress that the sample 
was not representative of the general population and 
that findings could not be extrapolated beyond this survey. 
The 329 respondents ranged in age from 16 to 58 years, 
with an average age of 25 years. Sixty-seven per cent were 
men, 59% lived in Dublin, 38% lived elsewhere in Ireland 
and 3% lived outside of Ireland. Just over half (51%) lived 
with their parents, 18% lived with a spouse or partner, 14% 
lived with friends and 10% lived alone. The majority (65%) 
were students, 26% were working or self-employed and 
6% were receiving a state benefit. Almost all (98%) were 
educated to leaving certificate or above. Among the 261 
(79%) respondents who had obtained a new psychoactive 
substance, the main sources were: head shops (78%), friends 
(66%), acquaintances (23%), online (17%) and/or dealers 
(15%). Seven had obtained new psychoactive substances 
through a home delivery service. Sixty-five per cent had 
access to a head shop within five kilometres of their home.
Fifty-seven per cent (186/329) of the sample had used 
one or more psychoactive powders at some time, 21% 
(68/329) in the month prior to the survey. Mephedrone 
was the most common powder used; 66% of respondents 
had tried it. Methylone was used by 10% of respondents. 
The most common methods of consumption were snorting 
(86%), and rubbing it on gums or the inside of the mouth 
(40%). Fifty-eight per cent consumed between 0.1 gram 
and 1 gram of powder in a typical session. Respondents 
reported a high frequency of undesirable (though not always 
unexpected) effects, including palpitations (68%), chest pain 
(17%), breathing difficulties (20%), anxiety (40%), paranoia 
(38%), aggression (19%), memory blackout (43%) and 
fainting or collapse (5%). Users also experienced  
come-down effects, including insomnia (74%) and low 
mood or depression (72%). 
What are the best structures to ensure ‘coherent’ drug 
policies?
The next phase of the PG enquiry will seek to develop a 
model to test the ‘coherence’ of policies on substance 
misuse, in other words the extent to which the different 
modes of integration are compatible, the extent to which 
the political and policy approaches are aligned. This 
approach does not presuppose the superiority of any 
particular policy framework. 
(Brigid Pike)
1. Muscat R and members of the Pompidou Group 
Research Platform (2008) From a policy on illegal drugs to 
a policy on psychoactive substances. Strasbourg: Council 
of Europe Publishing. 
2. See Pike B (2009) Illicit drugs, alcohol and tobacco – 
understanding the policy issues. Drugnet Ireland, (29): 3–4.
3. Muscat R, van de Mheen D, Barendregt C and members 
of the Pompidou Group Research Platform (2010) 
Towards an integrated policy on psychoactive substances: a 
theoretical and empirical analysis. Strasbourg: Council of 
Europe Publishing.
4. Muscat defines the new discipline as including elements 
of sociology, cognitive psychology and neuroscience.
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Forty-eight per cent (159/329) of the sample had used one 
or more psychoactive party pills or liquid highs at some time, 
12% (38/329) in the month prior to the survey. BZP was the 
most common party pill used; 37% of respondents had tried 
it. The most common methods of consuming a party pill 
were swallowing it whole (74%), snorting its contents (15%) 
and bombing it (13%). Two pills was the most common 
number taken in a typical session (night). Respondents 
reported a high number of undesirable effects, including 
palpitations (61%), chest pain (16%), breathing difficulties 
(11%), anxiety (39%), paranoia (36%), aggression (13%), 
memory blackout (28%) and fainting or collapse (6%). Users 
also experienced come-down effects, including insomnia 
(82%) and depression (70%). 
Only a small number of respondents who used powders, 
party pills or liquid highs sought formal medical assistance; 
for example, four attended a general practitioner, three 
attended an emergency department and seven attended a 
mental health professional. 
Powders, pills and liquid highs were most commonly 
consumed with friends (96%) and acquaintances (30%) and 
rarely with family (9%). They were consumed most often on 
Friday and Saturday nights and most often at parties (83%), 
but also at friends’ homes, festivals and clubs. 
Sixty per cent (197/329) of the sample had used one or 
more psychoactive smoking blends at some time, 15% 
(49/329) in the month prior to the survey. Smoke XXX 
(74%) was the most common blend used, followed closely 
by Spice (66%). 
Thirty-eight per cent (126/329) of the sample had used one 
or more psychoactive ethnobotanicals at some point in their 
life. Salvia divinorum (61%) was by far the most common 
plant used. 
The authors report a rapid and marked decrease in the 
number of head shops nationwide as a result of the Criminal 
Justice (Psychoactive Substances) Act 2010, and speculate on 
future effects of the Act:
•	 It is likely that there will be a concomitant decrease in 
the use of psychoactive substances by casual, young 
and first-time users, and an associated decrease in 
presentations to hospital emergency departments.
•	 Habitual users who were attracted by the legality and 
easy availability of head shop products are likely to 
return to ‘traditional’ illegal substances.
•	 A proportion of head shops’ customer base will 
take their business online, where chat rooms and 
blogs will keep them updated with new products, 
perceived effects, and recommended sources and 
avenues of delivery. (p.79)
Among the recommendations made in various sections of 
this report are those summarised below.
•	 Existing models of online monitoring to curtail online 
trading are examined, such as the model of co-
operation between the Irish Medicines Board and the 
Customs authorities to monitor the sale of counterfeit 
medicines and other psychoactive substances.
•	 The Department of Health monitors the emergence 
of new head shop products and moves speedily to 
control their use.
•	 A centralised national database to collect data from 
emergency departments on alcohol and other drug use 
is developed and managed by an appropriate agency. 
This would facilitate the verification of the harm being 
caused by existing and newly emerging drugs.
•	 The HSE National Drugs Awareness Campaign takes 
account of users’ experiences of new psychoactive 
drugs. Also, online campaigns such as drugs.ie should 
highlight the dangers of new psychoactive drugs as 
identified in this report.
•	 Ireland should review the proposed legislation in the 
UK which would allow the temporary banning of 
new psychoactive substances while they are being 
fully assessed for their harmful effects.
(Jean Long and Johnny Connolly)
1. Kelleher C, Christie R, Lalor K, Fox J, Bowden M 
and O’Donnell C (2011) An overview of psychoactive 
substances and outlets supplying them. Dublin: National 
Advisory Committee on Drugs.  
www.drugsandalcohol.ie/15390
Acute liver failure following recreational 
use of psychotropic ‘head shop’ compounds
Fröhlich and colleagues1 report the case of a young man 
who presented with acute psychosis and subsequently 
developed hepatic failure following ingestion of butylone 
and MDPV (methylenedioxypyrovalerone). These substances 
were banned in Ireland under legislation that came into 
effect on 23 August 2010. 
The patient was a 28-year-old male suffering from bipolar 
affective disorder but otherwise healthy. Following ingestion 
of 12 tablets he had a seizure. On arrival to hospital his 
neurological assessment (GCS) was 5 out of a possible 15, 
his heart rate was 190 beats per minute, systolic blood 
pressure 230 mmHg, temperature 39.5°C and he was 
sweating profusely. He was treated in the intensive care 
unit, with cooling (to reduce his temperature), mechanical 
ventilation (to assist his breathing), labetalol (to reduce his 
blood pressure) and phenytoin (to manage his seizures). 
His urine and blood were tested for standard drugs did not 
reveal any evidence of MDMA, cocaine, paracetamol, or 
salicylates. The tablets taken were examined and contained 
butylone and MDPV which are stimulant type drugs. After 
ten hours his neurological and respiratory status was normal. 
On day 2, he developed rhabdomyolysis, a condition 
which can be associated with stimulant use, in which 
damaged skeletal muscle tissue breaks down rapidly. 
Unexpectedly, between day 2 and day 3, the patient 
developed acute liver failure. Following treatment for three 
days with N-acetylcysteine infusion (normally used as a 
treatment for paracetamol overdose), his liver functions 
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Report on innovative project in response 
to benzodiazepine use
The GP–Community Partnership Addiction Project was set 
up in Ballymun in 2006 in response to concerns about the 
acceptance and normalisation of benzodiazepine use in the 
area, as highlighted in a study published by the Ballymun 
Youth Action Project (BYAP) in 2004.1 Benzodiazepines are 
among the most commonly prescribed drugs; they are used 
to treat conditions such as anxiety, depression or insomnia. 
While they are safe for short-term use, the risk of abuse and 
dependence as a result of inappropriate long-term use has 
been well documented. The Ballymun Family Practice took 
part in this project funded by the Ballymun Local Drugs Task 
Force in search of a non-pharmaceutical alternative to 
benzodiazepine prescribing. A report outlining the project 
and analysing the outcomes of its first three years was 
published in June 2011.2 The project includes:
•	 providing general practitioners (GPs) with training  
in motivational interviewing;
•	 providing a free counselling service within the GP 
practices;
•	 inviting long-term users of benzodiazepines to review 
and discuss their need for prescribed medication 
and, to some users, also offering onsite counselling 
service;
•	 assessing, through quantitative and qualitative 
research, the impact of the letter and of the 
counselling service on reducing benzodiazepine use.
GPs in the four general practices that make up the Ballymun 
Family Practice identified 134 long-term benzodiazepine 
users among their patients. This sample was then divided 
into two groups: people in Group 1 (n=54) were sent a letter 
advising them to consider their current benzodiazepine use; 
people in Group 2 (n=80) were sent the same letter with 
an added paragraph offering the services of a counsellor. 
Prescriptions were monitored for the year before the letters 
were sent and for six months afterwards. In the six month, 
post-letter period, just over 29% of patients in Group 1 and 
over 38% in Group 2 reduced their benzodiazepine use. 
The letter resulted in lower prescription rates, and the offer of 
onsite counselling reinforced the positive impact of the letter.
Looking in more depth at the patients’ profiles, it appears 
that the initiative was more effective among younger 
benzodiazepine users who were on a methadone 
maintenance programme. There was a clear positive 
outcome for patients who used or had used multiple 
substances, including opiates, and who may have been more 
willing to address their benzodiazepine use 
as part of their overall addiction problem.
The project had less impact among older 
patients who had been on low doses 
of benzodiazepine for many years and 
were not receiving medical treatment for 
problem use of other substances. Reducing 
benzodiazepine use for this cohort involves 
tackling long-term health beliefs or a so-
called ‘culture of benzodiazepine use’, a 
more complex undertaking that can only 
achieve results over a longer period.
The quantitative data on benzodiazepine 
prescription rates was complemented by qualitative 
research. Feedback from focus groups with GPs and in-depth 
interviews with two addiction counsellors emphasised 
the fact that having the addiction counsellors on site was 
a key element of the project. The nature and extent of 
integration of the counselling service within the GP practice 
was reported as very positive and complementary to both 
services. Counsellors were part of the team, while GPs felt 
more empowered and welcomed the much-needed support 
in treating addictions in general. In addition to the practical 
benefits to patients and practitioners, the service integration 
contributed to the effectiveness of the project, through early 
identification and intervention, and made referrals easier. 
The additional training provided to GPs was reported to be 
very helpful in the selection of referrals, and improvements 
in the referral process had in turn a positive impact on 
attendance levels.
Benzodiazepine use and its reduction is a complex issue. 
The project demonstrated positive outcomes for long-term 
benzodiazepine patients and it was particularly successful for 
patients who were battling other addictions. 
While focusing on benzodiazepine use in Ballymun, this 
project provides relevant evidence-based information that 
can help communities respond to the issue of drug use. 
It is clear that the integration of addiction counselling in 
a primary care setting is beneficial, and that simple cost-
effective interventions, such as the letter in this case, can 
make a difference. As said in the report (p. 40), ‘the project 
provided a tangible way of developing and fostering links in 
the community and promoted a multidisciplinary approach 
to the issue of drug use’.
tests slowly returned to normal. Following treatment to 
manage liver failure, the patient was discharged from 
the intensive care to psychiatric care where he received 
treatment for a relapse of his psychosis thought to be 
triggered by consumption of butylone and MDPV. According 
to the authors, this is the first case report associating these 
compounds with acute liver failure. There is no record in the 
literature of these compounds being associated with liver 
injury. However, MDMA, which is structurally similar  
to MDPV, is known to be toxic to the liver.
(Jean Long)
1. Fröhlich S, Lambe E and O’Dea J (2011) Acute liver failure 
following recreational use of psychotropic ‘head shop’ 
compounds. Irish Journal of Medical Science, 180(1): 
263–264.
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Jane Carrigan, researcher and author of the report, 
described the project as a very challenging and interesting 
experience for researchers, GPs, and counsellors alike. The 
patients’ perspective was not included in this analysis, an 
element that may be included in future research. At the 
launch of the report by Minister of State Róisín Shortall, 
Andrew Montague, chair of Ballymun Local Drugs Task 
Force, Jacintha Harte, addiction counsellor, and Dermot 
King, interim director of BYAP, all emphasised the positive 
feedback from all practitioners and expressed hopes that 
such initiatives might lead the way in informing and 
influencing the work of primary health care teams. Minister 
Shortall also reiterated the importance of data reporting and 
research in the area of drug treatment as a stepping stone 
for improving policies and service planning.
(Delphine Bellerose)
1. Ballymun Youth Action Project (2004) Benzodiazepines 
– whose little helper? The role of benzodiazepines in the 
development of substance misuse problems in Ballymun. 
Dublin: National Advisory Committee on Drugs.  
www.drugsandalcohol.ie/5898
2. Carrigan J (2011) Chains of addiction & links of support: 
responding to benzodiazepine use in Ballymun. A 
GP–Community Partnership Addiction Project. Dublin: 
Ballymun Local Drugs Task Force and Ballymun Family 
Practice. www.drugsandalcohol.ie/15361 
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Non-fatal overdoses and drug-related 
emergencies
Data extracted from the Hospital In-Patient Enquiry (HIPE) 
scheme were analysed to determine trends in non-fatal 
overdoses discharged from Irish hospitals in 2009. There 
were 4,202 overdose cases in that year, of which 30 died 
in hospital. The 4,172 discharged cases are included in this 
analysis. The number of overdose cases decreased by 13% 
between 2008 and 2009 (Figure 1).
Characteristics of cases
Gender
In the years 2005–2009 there were more overdose cases 
among females than among males (Figure 2), with females 
accounting for 54% of all overdose cases in 2009.
Age group
In the four-year period 2005–2008, one quarter of overdoses 
occurred in those aged 15–24 years, with the incidence of 
overdose decreasing with age (Figure 3). The number of 
under-25s fell in 2009, accounting for 32% (n=1,328) of 
overdose cases, compared to 40% (n=2,015) in 2005.
Figure 1 Overdose cases by year, 2005–2009 
(N=23,714)
Source: Unpublished HIPE data
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Figure 2 Overdose cases by gender, 2005–2009 
(N=23,714)
Source: Unpublished HIPE data
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Figure 3 Overdose cases by age group, 2005–2009 (N=24,314)
Source: Unpublished HIPE data
200
400
600
800
1000
1200
0
1400
2005
2008
2006
2007
1275
15–24
1269
1287
1233
975
1017
25–34
942
995
1026
887
882
35–44
835
893
867
845
581
45–54
575
624
543
576
282
55–64
273
312
274
281
740
701
550
560
353
0–14
N
um
be
r
2009
140
65–74
126
136
148
140
70
75–84
98
99
90
85
25
85+
21
22
31
30
x
x
x
x
x
x
x
x
Drugs involved
Table 1 presents the positive findings per category of drugs 
and other substances involved in all cases of overdose in 
2009. Non-opioid analgesics were present in 36% (1,518) of 
cases. Paracetamol is included in this drug category and was 
present in 27% (1,129) of cases. Psychotropic agents were 
taken in 22% (903) and benzodiazepines in 25% (1,053) of 
cases. There was evidence of alcohol consumption in 13% 
(534) of cases. Cases involving alcohol are included in this 
analysis only when the alcohol was used in conjunction with 
another substance.
Drug category Positive findings per drug category*
n %
Non-opioid analgesics 1518 36.4
Benzodiazepines 1053 25.2
Psychotropic agents 903 21.6
Anti-epileptic / Sedative / Anti-Parkinson agents 556 13.3
Narcotics and hallucinogens 539 12.9
Alcohol 534 12.8
Systemic and haematological agents 201 4.8
Cardiovascular agents 158 3.8
Autonomic nervous system agents 128 3.1
Anaesthetics 116 2.8
Hormones 100 2.4
Systemic antibiotics 94 2.3
Gastrointestinal agents 74 1.8
Other chemicals and noxious substance 58 1.4
Diuretics 51 1.2
Muscle and respiratory agents 45 1.1
Topical agents 25 0.6
Anti-infectives / Anti-parasitics 23 0.6
Other gases and vapours 7 0.2
Other and unspecified drugs 981 23.5
*  The sum of positive findings is greater than the total number of cases because some cases involved more than  
one drug or substance. 
Source: Unpublished data from HIPE
Table 1 Category of drugs involved in overdose cases, 2009 (N=4,172)
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Overdoses involving narcotics or hallucinogens
Narcotic or hallucinogenic drugs were involved in 13% 
(539) of overdose cases in 2009. Figure 4 shows the number 
of positive findings of drugs in this category among the 539 
cases. The sum of positive findings is greater than the total 
number of cases because some cases involved more than 
one drug from this category. Opiates were used in 82% of 
the cases, cocaine in 17% and cannabis in 9%.
Overdoses classified by intent
In 70.3% of cases the overdose was classified as intentional 
(Figure 5).
Table 2 presents the positive findings per category of drugs 
and other substances involved in cases of intentional 
overdose in 2009. Non-opioid analgesics were involved in 
43% (1,236) of cases, benzodiazepines in 28% (816) and 
psychotropic agents in 25% (728). 
Table 2 Category of drugs involved in intentional 
overdose cases, 2009 (N=2,879)
Drug category Positive findings per  
drug category*
n %
Non-opioid analgesics 1236 42.9
Benzodiazepines 816 28.3
Psychotropic agents 728 25.3
Anti-epileptic / Sedative / 
Anti-Parkinson agents
 
451
 
15.7
Alcohol 402 14.0
Narcotics and hallucinogens 293 10.2
Cardiovascular agents 99 3.4
Systemic and 
haematological agents
 
97
 
3.4
Autonomic nervous system 
agents
 
87
 
3.0
Systemic antibiotics 74 2.6
Hormones 71 2.5
Gastrointestinal agents 58 2.0
Anaesthetics 52 1.8
Other chemicals and 
noxious substances
 
41
 
1.4
Anti-infectives / Anti-
parasitics
 
29
 
1.0
Other gases and vapours 23 0.8
Muscle and respiratory 
agents
 
16
 
0.6
Topical agents 9 0.3
Diuretics 5 0.2
Other and unspecified drugs 606 21.0
*The sum of positive findings is greater than the total 
number of cases because some cases involved more than 
one drug or substance. 
Source: Unpublished data from HIPE
(Deirdre Mongan)
Figure 4 Narcotics and hallucinogens involved in 
overdose cases, 2009 (N=539)
Source: Unpublished data from HIPE
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Figure 5 Overdose cases by classification, 2009  
(N= 4,096)
Source: Unpublished data from HIPE
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Substance use among third-level 
students in Limerick
Houghton and colleagues1 examined students’ health and 
lifestyles in a quota sample survey2 that included questions 
on recent (within the last year) drug use. One thousand 
students attending lectures were asked to participate in the 
survey and 76% (742) did so. Participants ranged in age 
from 17 to 63 years and half were aged 20 or under. Fifty-
two per cent (386) were men. Five (0.7%) reported that 
they had taken ‘Revelin’ (the name of a dummy drug) and 
these were excluded from the analysis. 
Cannabis was the most common illegal drug taken; one-
third of students reported having taken it at least once in 
the year prior to the survey (Table 1). Cocaine was also 
commonly used, with 13% taking it during the same 
time period. Ecstasy was taken by 12% of respondents. 
Similar proportions took magic mushrooms (7%) and 
amphetamines (7%). Five per cent were prescribed 
tranquillisers and 3% took tranquillisers that were not 
prescribed for them. Similar proportions took LSD and 
solvents. Only 0.9% took heroin, and 0.5% injected an illicit 
drug, in the last year. Almost 18% of respondents took more 
than one drug concurrently (polydrug use).  
Men were marginally more likely to take drugs than women. 
The authors state that the high rates of drug use have 
implications for physical and mental health. 
(Jean Long)
1. Houghton F, Keane N, Murphy N, Houghton S and 
Dunne C (2011) 12 month prevalence of drug use 
among third-level students in Limerick City. Irish  
Medical Journal, 104 (5).  
www.drugsandalcohol.ie/15300
2. See also two short papers by Houghton et al. (2010)  
on alcohol use and smoking among the same sample  
of students in National Institute of Health Sciences 
Research Bulletin, 5(4):104–107.  
www.nihs.ie/researchbulletin/index/cfm
Table 1 Drug type and frequency of use in the last year by third-level students surveyed
All Male Female
Drug type Never 1 or 2 
times
3 or 
more 
times
Never 1 or 2 
times
3 or more 
times
Never 1 or 2 
times
3 or 
more 
times
% (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n)
Cannabis 66.8 (412) 11.2 (69) 22.1(136) 67.9 (226) 9.9 (33) 22.2 (74) 65.6(177) 13.0(35) 21.5 (58)
Cocaine 87.0 (562) 7.3 (47) 5.7 (37) 87.1(311) 5.6 (20) 7.3 (26) 87.0(240) 9.8 (27) 3.3 (9)
Ecstasy 87.6 (567) 6.3 (41) 6.0 (39) 85.7 (306) 7.3 (26) 7.0 (25) 90.3(250) 5.4(15) 4.3 (12)
Magic 
mushrooms 92.9 (598) 5.1 (33) 2.0 (13) 91.9 (327) 5.6 (20) 2.5 (9) 94.2(268) 4.7(13) 1.1 (3)
Amphetamine 93.0 (599) 4.2 (27) 2.8 (18) 91.6 (327) 5.0 (18) 3.4 (12) 94.9(261) 3.3 (9) 1.8 (5)
Tranquillisers 
with 
prescription 94.9 (610) 3.6 (23) 1.4 (9) 95.2 (338) 3.7 (13) 1.1 (4) 94.5(260)  3.6(10) 1.5 (4)
Tranquillisers 
without 
prescription 96.9 (622) 2.3 (15) 0.8 (5) 96.6(344)  2.2 (8) 1.1 (4) 97.4(267)  2.2 (6) 0.4 (1)
LSD 96.3 (620) 2.0 (13) 1.7 (11) 95.5 (341)  2.5 (9) 2.0 (7) 97.5(268)  1.5 (4) 1.1 (3)
Solvents 96.3 (619) 2.5 (16) 1.1 (7) 95.5 (340)  2.8 (10) 1.4 (5) 97.1(268)  2.2 (6) 0.7 (2)
Heroin 99.1 (638) 0.6 (4) 0.3 (2) 98.6(352)  1.1 (4) 0.3 (1) 99.6(274)  0.4 (1)  0 (0)
Drugs by 
injection 99.5 (642) 0.3 (2) 0.2 (1) 99.4(355)  0.3 (1) 0.3 (1) 99.6(275)  0.4 (1)  0 (0)
Source: Adapted from Houghton et al. (2011)
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Exploring illicit drug use in a  
Traveller community
 Walsh1 set out to explore the nature 
of illicit drug use within one Traveller 
community in the greater Dublin area 
and assess the relative merits of 
mainstream drug services and 
Traveller-specific drug services. 
Data were collected through semi-
structured interviews with seven 
female and seven male Travellers.  
Four of the men were using a local 
drug service. The remaining three 
men and the seven women were not using drug services and 
did not report any form of illicit drug use. In addition, seven 
service providers were interviewed. 
Perceptions of illicit drug use in the community and  
the implications for research 
There was a perception among interviewees, particularly 
among service providers, that illicit drug use within the 
Traveller community was closely associated with the 
marginal status accorded to members of the community  
by sections of mainstream society. 
Among the four male drug-using Travellers interviewed, 
cocaine was perceived as the drug most used in their 
community, followed by cannabis, ecstasy and prescription 
tablets, with a few using heroin. They said that these drugs 
were primarily used as part of the social and recreational 
night-out scene, but expressed fears about the likely 
impact of heroin use if it became more prevalent. Smoking 
cannabis was perceived to be part of normal activity in the 
community. 
All but one of the interviewees believed that illicit drug 
use within the local Traveller community was confined to 
men. The one dissenting male agreed that illicit drug use 
was predominantly a male activity; however, he mentioned 
being aware of plenty of Traveller women who used illicit 
drugs. The Traveller women interviewed were of the view 
that it would be highly unusual for women to get involved 
in illicit drug use. The perception that illicit drug use among 
Traveller women is not a common activity was also reported 
by Fountain2 and Van Hout3 However; all three studies have 
an over-reliance on the perceptions of service providers and 
non-drug-using members of the Traveller community, with 
only minimal data provided by drug-using Travellers. 
All three studies reported difficulties in securing access to 
drug-using Travellers. Both Fountain and Walsh relied almost 
exclusively on Traveller advocacy organisations, service 
providers and non-drug-using Travellers as ‘gatekeepers’ to 
secure access to drug-using Travellers. Perhaps drug-using 
Travellers, both male and female, are reluctant to disclose 
their use of illicit drugs to such organisations and to non-
drug-using members of their own communities because of 
the stigma that surrounds such activity. If this is the case, 
then perhaps the use of research techniques that are closer 
to the ethnographic position or ‘snowball sampling’ where 
a sample of drug-using Travellers is built up over time using 
one contact to secure access to others, would be more 
appropriate. An over-reliance on the perceptions of service 
providers and non-drug-using Travellers, rather than on 
the experiences of drug-using Travellers, has implications 
for both the quality and usability of the research being 
undertaken. Such reliance could mean that the nature of 
illicit drug use could remain under-reported and poorly 
understood; indeed Fountain (2006) mentions that service 
providers were often unable to differentiate between 
problematic and non-problematic illicit drug use. 
Perceptions of the supply of illicit drugs
Interviewees had mixed views about how illicit drugs were 
being supplied within the local community. Some Travellers 
believed that other Travellers were dealing drugs in the 
community; other interviewees felt that drugs were being 
purchased from the settled community. The four male 
drug-using Travellers recalled their experiences of being 
introduced to illicit drug use (often ecstasy or cocaine) 
through contacts with members of the settled community. 
Perceptions of the potential impact of illicit drug use
The negative image of Traveller men using illicit drugs and 
the potential impact of this image on young children was 
cited as a key concern by the Traveller women; fears were 
also expressed that an escalation in illicit drug use could 
contribute to an increase in conflict and criminal activity 
within the community. 
Service provision for illicit drug use in the community
Service providers not working directly with drug-using 
Travellers were in favour of Traveller-specific drug services, 
whereas two service providers working directly with drug-
using Travellers favoured mainstream drug services as they 
could offer more privacy and confidentiality, a view endorsed 
by all the Travellers interviewed. Three of the four male drug-
using Travellers were using a mainstream drug service on the 
recommendation of other Travellers. 
Traveller culture and identity as potential protective 
factors 
Retaining traditional religious values and practices, a close-
knit style of family life and the strong role of women in 
preserving the family were mentioned as distinct cultural 
aspects of the Traveller community. There was a perception 
that families that adhered to religious practices and had 
fewer interactions with the settled community also protected 
themselves from the use of illicit drugs. There was a degree 
of consensus that the influence of Traveller women, both 
as mothers and as wives, can deter the men from using 
illicit drugs. For example, the fear of the wife leaving the 
husband was cited as an example of this protective capacity. 
It was acknowledged by some that despite the advantages 
of familial closeness, drawbacks included a lack of personal 
privacy and individuality. 
Because of the methodological limitations of this study, 
it can be argued that it is more of a snapshot of untested 
perceptions than an exploratory analysis of the nature of 
illicit drug use within this community. 
(Martin Keane)
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1. Walsh B (2010) Cultural dislocation and consequences: an 
exploratory study of illicit drug activity among a Traveller 
community in North Dublin. Dublin: Blanchardstown Local 
Drugs Task Force. www.drugsandalcohol.ie/15530
2. Fountain J (2006) An overview of the nature and extent 
of illicit drug use amongst the Traveller community: an 
exploratory study. Dublin: Stationery Office.  
www.drugsandalcohol.ie/3958
3. Van Hout MC (2009) Irish Travellers and drug use –  
an exploratory study. Ethnicity and Inequalities in  
Health and Social Care, 2(1): 42–49.
UK expert group reports on recovery-
oriented treatment
 The UK National Treatment Agency 
(NTA) has published an interim report 
by Professor John Strang,1 chair of an 
expert group set up in 2010 ‘to provide 
guidance to the drug treatment field on 
the proper use of medications to aid 
recovery and on how the care for those 
in need of effective and evidence-based 
drug treatments is more fully orientated 
to optimise recovery’ (p.2). The author 
makes ‘some early observations’ under 
three key headings: consensus reached 
on a number of issues, how services can improve the quality 
of treatment offered in the short term, and a vision of what 
recovery-orientated services can become. These observations 
are summarised below. 
Consensus on a number of issues
The group acknowledged the strong body of evidence that 
supports the effectiveness of opiod substitution treatment 
(OST) and seeks to build on this evidence to develop a 
recovery platform which will achieve even greater outcomes. 
It recognised the expansion in treatment services in the UK 
and the benefits to patients through a concerted drive to 
reduce waiting lists and improve retention in treatment. It 
also acknowledged, that, in some instances, there has been 
an over reliance by clinicians on prescribing medication, and 
‘patients being allowed to drift into long-term maintenance’ 
(p.3). The group shared the view that ‘the prescribing of 
any medication (and perhaps especially of OST) must not 
be allowed to become detached and delivered in isolation 
from other crucial components of effective treatment. 
Other elements of overall care need also to be considered, 
including individual recovery care planning, psychosocial 
interventions and integration with mutual help-groups and 
peer- support’ (p.3).
Key elements of effective drug treatment
A comprehensive individual needs assessment that is 
undertaken early and is ongoing throughout treatment is 
a key part of the treatment process. The group is agreed 
that ‘assessment should not be a process that happens to 
someone but one in which they are actively involved’ (p.4). 
A recovery plan tailored to the patient’s needs must be 
developed collaboratively between the clinician and the 
patient and should be reviewed regularly and revised when 
appropriate. This report repeatedly stresses the importance 
of regular reviews of the recovery plan: ‘if an individual is 
deriving little or no benefit from an intervention, then it 
should be modified and tailored in partnership with the 
patient so that the provision of treatment delivers identified 
and valued benefit’ (p.4). 
The group recognised that the eventual package of recovery-
orientated treatment services was likely to appear complex 
to service providers, and that services will need time to 
adjust and will require training to reorient themselves 
towards a balance between harm reduction (reduction of 
negatives) and recovery (accrual of positives). The report lists 
some immediate steps services can take to begin to strike 
this balance. These are summarised below. 
1. Undertake an audit of your service to assess the current 
balance between overcoming dependence (recovery) 
and reducing harm to ensure that both objectives  
co-exist. 
2. Review all your patients to ensure they have achieved 
abstinence from their main problem drug(s) or are 
actively working to achieve abstinence. 
3. Consider changing the current balance between 
recovery and harm reduction to encourage more 
patients to pursue recovery. 
4. Let your patients see other patients who have successfully 
exited from treatment by linking your service to a recovery 
community, or employing ex-service users or using them 
as volunteers or as recovery mentors and coaches. 
5. Ensure adequate support is in place for patients who 
wish to reduce and/or stop using their medication and 
that rapid response mechanisms are in place in the event 
of relapse. 
6. Audit the availability of key psycho-social interventions 
using as a benchmark the interventions recommended 
by the National Institute of Clinical Excellence (NICE)2 
and the audit tool recommended by the NTA and the 
British Psychological Society.3
7. Strengthen and develop the social networks around patients 
including families and access to mutual-help groups.
8. Establish opportunities for patients to accrue social 
capital via employment placements, vocational training 
and volunteering.
9. Ensure all key workers are trained and supervised to 
deliver psychosocial interventions to a competent 
standard. Effective key working should also involve 
building collaborative interventions to develop the 
insight of patients and help them build a more 
integrated lifestyle by attending to their employment 
and housing needs. 
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A vision of what recovery-orientated services can become
The report outlines an eight-point vision for the future in 
which services will: 
•	 continue to recognise the role of prescribing 
medication, but not as an end in itself, rather as one 
component part in an integrated treatment package 
that minimises risk and promotes each patient’s 
recovery;
•	 develop and support staff to adopt and promote 
recovery among patients and train staff to deliver 
evidence-base psycho-social interventions alongside 
prescribed medication;
•	 make visible to all patients entering treatment the 
range of treatment and recovery options available 
and the likely trajectories through options and 
possible destinations; 
•	 maximise what individual can achieve with a clear 
emphasis on movement and progress for patients;
•	 recognise the achievement of preventing further 
deterioration in the most severely damaged patients;
•	 involve the families and carers of patients in their 
recovery planning;
•	 develop close links with the community to promote 
reintegration of all patients; and
•	 Work with clearly defined guidelines that will allocate 
clearly defined roles for medication in stabilising, 
maintaining, detoxing and preventing relapse  
among patients.
The report identifies four key issues which require further 
intensive consideration: (i) distinguishing between the 
proportion of patients who might be expected to recover 
rapidly with no or modest substitute prescribing and the 
proportion which may need long-term care, including 
substitute prescribing (this issue is being addressed by a 
sub-group of the main group), (ii) how can treatment help 
patients to build ‘recovery capital’, the social, physical, 
human and cultural resources seen as necessary to initiate 
and sustain recovery from addiction? (iii) how can recovery 
capital and its accumulation be measured? and (iv) how can 
treatment services decide who receives what intervention, 
when they receive it and how is it best delivered? The last 
three issues will continue to be addressed by the main body 
of the expert group. 
Recovery capital is mentioned as a key conceptual driver 
of their vision of recovery and further work on assessing 
how treatment services can help patients to develop 
recovery capital is underway through a sub-committee of 
the group. Drawing on the work of the French Sociologist 
Pierre Bourdieu and the concept of social capital, Cloud and 
Granfield (2008) 4 conceptualise recovery capital as the sum 
of resources necessary to initiate and sustain recovery from 
substance addiction. Recovery capital includes the social, 
physical, human and cultural resources needed to advance 
the recovery of drug users. Such resources include networks 
of non-drug using friends and supports (social capital), 
tangible assets such as secure accommodation and regular 
income through employment (physical capital), social and 
personal skills, education, mental and physical health and 
career goals and ambitions (human capital) and values, 
beliefs and attitudes that promotes social reintegration and 
the ability to live within socially prescribed norms (cultural 
capital). The full report on the work of the group is expected 
to be available towards the end of 2011 and will be covered 
in a later issue of Drugnet Ireland.
(Martin Keane)
1. Strang J (2011) Recovery-oriented drug treatment: an 
interim report. London: National Treatment Agency for 
Substance Misuse. www.drugsandalcohol.ie/15524
2. NICE (2007) Drug misuse: psychosocial interventions. Nice 
clinical guidelines 51. London: National Institute for 
Health and Clinical Excellence. www.nice.org.uk/CG51
3. Pilling S, Hesketh K and Mitcheson L (2010) Psychosocial 
interventions in drug misuse: a framework and toolkit for 
implementing NICE-recommended treatment interventions. 
London: National Treatment Agency for Substance 
Misuse and British Psychological Society.  
www.drugsandalcohol.ie/13622
4. Cloud W and Granfield R (2008) Conceptualising recovery 
capital: expansion of a theoretical construct. Substance 
Use and Misuse, 43(12–13): 1971–1986.
Updated Cochrane review of heroin 
maintenance treatment
Heroin was first prescribed for chronic opiate dependence in 
the UK back in 1926. By the 1960s the number of problem 
opiate users had increased, fuelling a black market in heroin 
which subsequently led to the introduction of restrictions. 
Thirty years later, clinical trials conducted in Switzerland 
and the UK re-opened the debate on the effectiveness of 
prescribed heroin for the treatment of problem opiate use. 
The original Cochrane review on this topic was published in 
2003; this update (published June 2011) integrates results 
from European and Canadian clinical trials.1 The objective 
was ‘to compare heroin maintenance to methadone or other 
substitution treatments for opioid dependence regarding: 
efficacy and acceptability, retaining patients in treatment, 
reducing the use of illicit substances, and improving health 
and social functioning’.
In all, 3,346 article titles and abstracts were screened, of 
which 22 were eligible for the review but only eight met 
the inclusion criteria.2 The methodology used followed the 
accepted Cochrane Review guidelines on search strategies, 
selection of studies, data extraction and management.3 
While most of the studies compared heroin (plus flexible 
doses of methadone) against oral methadone only, there 
were some variations.2 One study compared injectable 
heroin to a control group on a drug treatment waiting 
list, and one study compared supervised inhaled heroin 
and another injectable methadone to oral methadone. 
Depending on the outcome of interest, the relevant studies 
were included in the various pooled analyses carried out to 
investigate the effect of heroin maintenance treatment.
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1. Retention in treatment 
Analysis of the relevant studies (1,388 patients) found that 
clients on supervised injectable heroin plus flexible dose of 
methadone were retained in treatment longer compared 
to patients in oral methadone maintenance (RR 1.44 [95% 
CI 1.19, 1.75]).4 Compared to any other drug treatment, 
heroin (supervised or not) (1,535 patients) improved 
retention in treatment (RR 1.44 [95% CI 1.16, 1.79]).
2. Relapse to illicit drug use 
This was measured as self-reported illicit drug use (including 
illicit heroin). The authors decided that meta-analysis was 
not suitable to carry out on the pooled data for this outcome 
and therefore reported the results of each individual study. 
They found a statistically significant reduced use of illicit 
drug use in all the relevant studies in the groups on heroin 
maintenance compared to the groups on methadone 
maintenance. The different types of other illicit substances 
used were not identified in almost all of the studies. 
3. Mortality
In four relevant studies (1,477 patients) six deaths were 
recorded in the group on supervised injectable heroin 
maintenance, compared to 10 in the group on oral 
methadone maintenance. There was no statistically 
significant difference in mortality found between the 
injecting heroin group and the groups on oral methadone 
(RR 0.65 [95% CI 0.25, 1.69]) or on any other drug 
treatment (RR 0.78 [95% CI 0.32, 1.89]).
4. Adverse medical events related to the study 
medication
For this outcome measurement (type of adverse event not 
specified), only data from four studies could be pooled 
for meta-analysis, with the results from the other studies 
presented separately. The results from that analysis were that 
those in the supervised injectable group had a higher risk of 
adverse medical events than those in the oral methadone 
maintenance group (RR 14.42 [95% CI 2.74, 75.97]).
5. Secondary outcomes
Although the results could not be combined, the results of 
the appropriate studies indicated a reduction in criminal 
offences. The only other secondary outcome where 
prescribed heroin appeared to have a protect effect was for 
imprisonment, compared to other treatments.
Discussion
In relation to overall completeness and applicability of the 
evidence, the authors concluded that the studies included 
were able to answer the main review questions. The risk of 
bias was reduced because of the acceptable sample sizes of 
and the consistency of results across the included studies. 
One area that was lacking was a clearer description of the 
characteristics of clients who would most benefit from  
this intervention.
The authors concluded that there were statistically 
significant results which showed supervised injectable heroin 
plus flexible doses of methadone improved retention in 
treatment, and led to a reduction in rates of illicit drug use, 
criminal offending and imprisonment. This intervention 
would be of benefit to clients who have failed to remain in 
methadone treatment.
Some limitations to this mode of treatment were identified 
by the authors. The review showed the increased risk of 
adverse medical events, indicating that prescribed heroin 
should only be given in treatment centres that were 
equipped to deal with emergencies. Clients’ attempts to re-
integrate into society could be restricted by having to attend 
a treatment centre two or three times a day for injections. 
There are many factors related to non-compliance with 
drug treatment, including poverty, lack of family support 
and psychiatric co-morbidity. The authors considered that 
in the current climate of limited and diminishing resources, 
the appropriateness of providing a more expensive medical 
treatment rather than attempting to address the known 
social predicators of non-compliance and relapse. Other 
studies are anticipated on this topic. 
Implications for practice
•	 Prescribed heroin provides added value to 
methadone treatment;
•	 Risk-benefit of prescription heroin must be evaluated 
fully before implementation in clinical practice due to 
the higher rate of serious adverse events;
•	 Prescribed heroin should be considered for clients 
who are have failed to remain in methadone 
substitution treatment programmes;
•	 It should only be provided in treatment centres if 
proper follow-up is available;
•	 The capacity of treatment services and the cost of 
the programme must be assessed before provided 
prescribed heroin.
 (Suzi Lyons)
1. Ferri M, Davoli M and Perucci CA (2011) Heroin 
maintenance for chronic heroin-dependent individuals. 
Cochrane Database of Systematic Reviews 2010, Issue 8. 
Art. No.: CD003410. http://onlinelibrary.wiley.com
2. The studies included were: RIOTT (2010), NAOMI 
(2009), Haasen (2007), PEPSA (2006), CCBH (A) (2002), 
CCBH (B) (2002), Perneger (1998) and Hartnoll (1980). 
Once pooled, a total of 2007 participants were available 
for analysis. Further details and references of each study 
included can be found on pp. 25–41 of the review.
3. Higgins JPT and Green S (eds) (2008) Cochrane 
handbook for systematic reviews of interventions. Version 
5.1.0 [updated September 2009]. The Cochrane 
Collaboration. www.cochrane-handbook.org 
4. Risk Ratio (RR) and 95% Confidence Interval (95% CI).
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Keltoi residential rehabilitation 
programme: outcome study
Keltoi offers a residential therapeutic rehabilitation 
programme for problem opiate users, emphasising 
occupational work and with a strong focus on after-care  
and living drug-free. This study1 reports on follow-up 
interviews with clients who attended the programme 
between September 2002 and July 2004. It was done as  
part of a wider evaluation of the programme, which has 
already been published.2 
The study aim was to evaluate how effective the Keltoi 
programme had been in helping participants to remain 
drug free. During the evaluation period, 149 clients had 
entered Keltoi, 94 had participated in the original evaluation, 
and 80 of these participated in the follow-up interview, 
which was based on the Maudsley addiction profile (MAP). 
The interviews started in May 2004 and finished in July 
2009. The average time between discharge and follow-
up interview was 1.9 years (range 1.2 to 3.0 years). Two 
participants in the original evaluation had died before the 
follow-up interview took place, giving a mortality rate of 
2.1% for the 94 participants. There was no control group. 
Half (51.3%) of the interviewees self-reported as fully 
abstinent (defined as abstinence from all substances 
including alcohol and prescription substitution drugs)  
in the 30 days before the interview. Most (88.1%) were  
still in contact with some type of drug treatment service. 
Those who were abstinent reported higher levels of well-
being than those who reported that they were not abstinent. 
In the 30 days before the interview;
•	 five (6.3%) interviewees reported injecting;
•	 a lower proportion of those who were abstinent 
(3.8%) reported suicidal thoughts compared to the 
proportion who were not abstinent (18.8%);
•	 over two thirds (77.5%) of those interviewed 
reported no criminal activities; and
•	 half (50.0%) reported having undertaken paid 
employment.
Self-reported abstinence was recognised to be a limitation 
by the authors, but was felt to be reasonably reliable among 
this population as there were no negative consequences 
for the interviewees. Because of the methodology used it 
was not appropriate to undertake statistical analysis of the 
data looking for factors which might be associated with 
abstinence. The authors stated that, for the same reason, 
they were ‘wary of direct comparisons with the majority of 
current international literature’ (p. 358) in this area. This lack 
of comparability is an issue in many studies.
Compared to the completion rate among the abstinence 
cohort in the ROSIE study (66%),3 the rate of completion 
in Keltoi was higher (77%). The outcomes of the Keltoi also 
compare favourably with another Irish study, with Keltoi 
participants reporting abstinence rates of 51% at follow-up, 
compared to 23% in a study by Smyth et al.4
The authors found large gaps in outcome-based evaluations 
for treatment programmes in Ireland and recommended 
the introduction of a health outcomes monitoring system. 
They also concluded that the evidence from their studies 
and others done in this area showed that many of those who 
enter residential treatment do not have successful outcomes. 
It is important to find out what works and what does not 
work for different people.
(Suzi Lyons)
1. White E, Browne C, McKiernan B and Sweeney B 
(2011) Keltoi rehabilitation programme: post-discharge 
outcome study. Drugs: education, prevention and policy, 
Early online: 1–8. http://www.drugsandalcohol.ie/14766 
2. Sweeney B, Browne C, McKiernan B and White E (2007) 
Keltoi client evaluation study. Dublin: Health Service 
Executive. http://lenus.ie/hse/handle/10147/92643
3. Cox G, Comiskey C and Kelly P (2007) ROSIE Findings 3: 
summary of 1-year outcomes: abstinence modality. Dublin: 
National Advisory Committee on Drugs.  
www.drugsandalcohol.ie/11516 
4. Smyth BP, Barry J, Lane A, Cotter M, O’Neill M, Quinn C 
et al. (2005) In-patient treatment of opiate dependence: 
medium-term follow-up outcomes. British Journal of 
Psychiatry, 187: 360–365. www.drugsandalcohol.ie/6777
2. Skinner R, and Conlon L, Gibbons D and McDonald C 
(2011) Cannabis use and non-clinical dimensions of 
psychosis in university students presenting to primary 
care. Acta Psychiatrica Scandinavica, 123(1): 21–27.
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Drugs and crime data
This article looks at trends in reported drug offences 
and drug seizures for various periods between 2003 and 
2010. It should be noted that drug offence and seizure 
data are primarily a reflection of law enforcement activity. 
Consequently, they are affected in any given period by 
such factors as law enforcement resources, strategies and 
priorities, and by the vulnerability of drug users and drug 
traffickers to law enforcement activities. Having said that, 
drug seizures are seen as indirect indicators of the supply 
and availability of drugs.
Figures 1 and 2 show trends in proceedings for drug 
offences from 2004 to 2009. As can be seen from Figure 1, 
criminal proceedings for the possession of drugs for personal 
use (simple possession) decreased in 2009 for the first time 
since 2004. Proceedings for drug supply also decreased 
marginally, from 2,964 in 2008 to 2,721 in 2009, when they 
returned to the 2007 level. Possession offences accounted 
for 74.5% of total drug offences in 2009.
Figure 2 shows trends in legal proceedings for a selection of 
other drug offences between 2004 and 2009.
The offence of obstructing the lawful exercise of a power 
conferred by the Misuse of Drugs Act 1977 (s.21) continues 
to account for a large majority of offences each year. 
Obstruction offences often involve an alleged offender 
resisting a drug search or an arrest or attempting to dispose 
of drugs to evade detection. Following a decline in 2008, 
proceedings for such offences increased in 2009, as they did 
for cultivation offences and forged prescription offences.
Importation offences decreased marginally in 2009. 
Proceedings for the cultivation or manufacture of drugs 
have continued to increase, rising from 29 in 2005 to 163 
in 2009. It is unclear whether this increase reflects a genuine 
growth in the commission of such offences or a sustained 
concentration of law enforcement on detecting them. 
Drug offence data can assist in understanding aspects of 
the operation of the illicit drug market in Ireland.1 Data on 
drug offence prosecutions by Garda division are a possible 
indicator of national drug distribution patterns. While these 
data primarily reflect law enforcement activities and the 
relative ease of detection of different drugs, when compared 
with other sources such as drug treatment data, for 
example, they can show us trends in market developments 
throughout the State. Such data can also indicate trafficking 
patterns by showing whether there is a concentration of 
prosecutions along specific routes. Figures 3 and 4 show 
trends in relevant legal proceedings for possession of drugs 
by Garda region. It should be noted that possession includes 
possession for personal use and possession for the purpose 
of supply. It is not possible to distinguish these two offences 
in the data reported by Garda region. However, as shown in 
Figure 1 above, it is generally the case that in 70-75%  
of all possession cases the drugs are deemed to be for 
personal use. 
Figure 1 Trends in relevant legal proceedings for 
total drug offences and for possession and 
supply offences, 2004–2009
Source: CSO (2008, 2009, 2010, 2011) www.cso.ie
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Figure 2 Trends in relevant legal proceedings for 
selected drug offences, 2004–2009 
Source: CSO (2008, 2009, 2010, 2011) www.cso.ie
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Drugs>and>crime>data>(continued)
It can be seen from Figures 3 and 4 that prosecutions for 
possession decreased in all but two Garda regions (the 
Northern and the South Eastern) in 2009, after a steady 
increase since 2006.
The Dublin Metropolitan Region still accounts for the 
majority of prosecutions for possession in the state. However, 
the proportion of prosecutions taking place outside the 
capital has increased significantly, from 43.6% in 2003  
to 63.3% in 2009. These data show that the drug 
phenomenon is now more widely distributed throughout 
the state than previously. 
Drug driving offences
Figure 5 shows the trend in prosecutions for driving under 
the influence of drugs (DUID) between 2005 and 2009, 
when the number rose from 70 to 695, an increase of more 
than 900%. It is unclear why this increase has occurred. It 
could be due either to an increase in the incidence of DUID 
or, the more likely possibility, an increase in targeted police 
activity in this area.
The new programme for government, Government for 
National Recovery 2011–2016, contains a number of actions 
related to criminal justice and drugs policy.2 The following is 
included as an action:
We will introduce roadside drug testing programmes to combat 
the problem of driving under the influence of drugs.
The development of reliable roadside testing procedure 
has been a challenging issue for many countries. At present 
the Garda Síochána, the Department of Transport and the 
Medical Bureau of Road Safety are collaborating in the 
development of a scheme to introduce US-style roadside 
testing of suspected drug drivers to accompany roadside 
alcohol tests. 
Drug seizures 
Cannabis seizures account for the largest proportion of all 
drugs seized. Figure 6 shows trends in cannabis-related 
seizures and total seizures between 2003 and 2010. The 
decrease and levelling out in total seizures between 2008 
and 2010 can partly be explained by the parallel trend in 
cannabis seizures during the same period. It is not clear if 
the reduction in cannabis-related seizures reflects a decline 
in cannabis use or a reduction in law enforcement activity 
targeted at the cannabis market. However, it should be 
noted that drug offence prosecutions reported above, most 
of which are cannabis-related, also decreased slightly in 
2009, with figures for 2010 not currently available.
Figure 3 Trends in relevant legal proceedings for 
possession of drugs, by Garda region 
excluding the Dublin Metropolitan Region, 
2003–2009
Source: Central Statistics Office
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Figure 4 Trends in relevant legal proceedings 
for possession of drugs in the Dublin 
Metropolitan Region and nationally, 
2003–2009
Source: Central Statistics Office
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Figure 5 Trends in relevant legal proceedings for 
driving in charge of a vehicle under the 
influence of drugs 2005–2009 
Source: CSO (2011) 
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The reduction in the total number of reported seizures in 
2009 and its levelling off in 2010 may also be explained by 
a reduction in the number of seizures of other drugs since 
2008. Figure 7 shows trends in seizures for a selection of 
drugs, excluding cannabis, between 2003 and 2010. There 
has been a significant decline in seizures of cocaine, heroin 
and ecstasy-type substances since 2007. It appears that the 
significant reduction in total drug seizures reported in 2009 
can be explained primarily as the result of a reduction in 
seizures of cannabis and cocaine. However, in 2010 we have 
seen the continued decline in heroin seizures. It is unclear 
whether this reflects a decline in heroin use or a change in 
law enforcement activities or some other factor.
(Johnny Connolly)
1. Connolly J (2005) The illicit drug market in Ireland.  
HRB Overview Series 2. Dublin: Health Research Board.
www.drugsandalcohol.ie/6018
 
2. Fine Gael and the Labour Party (2011) Towards recovery: 
programme for a national government 2011–2016.  
www.drugsandalcohol.ie/14795
Figure 6 Trends in the total number of drug seizures 
and cannabis seizures, 2005–2010 
Source: Central Statistics Office (2008, 2009, 2010);  
An Garda Síochána (2011) 
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Figure 7 Trends in the number of seizures of selected 
drugs, excluding cannabis, 2003–2010
Source: Central Statistics Office (2008, 2009, 2010);  
An Garda Síochána (2011) 
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Courts Service annual report 2010
The Courts Service annual report for 2010 provides statistics 
on the outcomes of prosecutions for drug offences between 
January and December 2010.1 Table 1 shows the outcomes 
of trials in 16,939 drug offence cases prosecuted in the 
District Court, the lowest court in the criminal justice system 
where most drug offences are dealt with. The most common 
outcome for drug offences in the District Court in 2010 
were cases being struck out, which made up 22.6% (3834) 
of case outcomes followed by fines, which accounted for 
19.2% (3249) of outcomes. Almost 10% of cases (1,588) led 
to a sentence of imprisonment. 
The Courts Service reports that 1,186 drug offences were 
tried in the Circuit Court, which has a higher jurisdiction 
than the District Court and can thus impose more severe 
sentences. Of those prosecutions, 767 led to guilty pleas. 
Of the 46 cases which went to trial, 14 were convicted, 
14 acquitted and 18 led to a nolle prosequi, where the 
prosecution enters a stay on criminal proceedings. It is 
unclear from the data provided what sentence was imposed 
in relation to the 14 convictions.
(Johnny Connolly)
1. Courts Service (2011) Courts Service annual report 2010. 
Dublin: Courts Service. www.courts.ie
Table 1 Sentences for drug offences in the District Court, 2010
Sentence Imprisonment Fine Community 
service/ 
probation
Struck 
out
Dismissed Taken into 
consideration*
Other Peace 
bond
Total
Number of 
offences 1588 3249 2107 3834 310 2460 2997 394 16939
* Taken into consideration: Section 8 of the Criminal Justice Act 1951 provides that where a person, on being convicted 
of an offence, admits himself guilty of any other offence and asks to have it taken into consideration in awarding 
punishment, the Court may take it into consideration accordingly. If the Court takes an offence into consideration, a note 
of that fact is made and filed with the record of the sentence, and the accused cannot be prosecuted for that offence, 
unless his conviction is reversed on appeal.
Source: Courts Service (2011)
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National Registry of Deliberate Self 
Harm annual report 2010
The ninth annual report from the National Registry 
of Deliberate Self Harm was published in July 2011.1 
The report contains information relating to every 
recorded presentation of deliberate self-harm to 
acute hospital emergency departments in 2010, 
giving complete national coverage of cases treated. 
In 2010, there were 11,966 recorded presentations of 
deliberate self-harm, involving 9,630 individuals. The 
rate of presentations increased from 209/100,000 of 
the population in 2009 to 217/100,000 in 2010, a 
4% increase. Of the 9,630 individuals who presented, 
86% were presenting for the first time in their life. 
Concordant with previous reports, 47% of self-
harm presentations in 2010 were men and the 
same proportion (47%) were aged under 30 
years. Two hundred and seventy five (2.3%) were 
living in homeless hostels or had no fixed abode. 
Presentations peaked in the hours around 10pm 
and were highest on Sundays and Mondays; 32% 
of episodes occurred on these two days. There was 
evidence of alcohol consumption in 41% of all 
presentations and this was more common among 
men (44%) than women (37%).
Drug overdose was the most common form of 
deliberate self-harm, occurring in 71% (8,538) of 
all such episodes reported in 2010. Overdose rates 
were higher among women (77%) than among 
men (65%). In 73% of cases the total number of 
tablets taken was known; an average of 31 tablets 
was taken in these cases. Forty-two per cent of all 
drug overdoses involved a minor tranquilliser, 29% 
involved paracetamol-containing medicines and 
21% involved anti-depressants or mood stabilisers. 
The number of deliberate self-harm presentations 
involving street drugs increased in 2009 (579) and 
again in 2010 (645) when compared to 2008 (461). 
Men are much more likely than women to self-harm 
using street drugs.
The next step, or referral outcome, was recorded for 
90% of deliberate overdose cases: over two fifths 
(41%) were discharged home; 37% were admitted 
to an acute general hospital; 7% were admitted to 
psychiatric in-patient care; a small proportion (0.6%) 
refused admission to hospital; and 14% discharged 
themselves before receiving referral advice.
The report recommends the following measures to 
reduce the incidence of deliberate self-harm:
 ■ A wide range of evidence-based treatments and 
aftercare programmes; 
 ■ Uniform assessment and aftercare procedures;
 ■ Adequate services to deal with alcohol and 
depression at peak admission times;
 ■ Information campaigns for the general public on 
the common symptoms of depression and signs 
of suicidal behaviour, and places where help  
is available.
 ■ A national strategy to deal with alcohol supply 
and illegal alcohol use among children under  
18 years.
(Jean Long and Ena Lyn)
1. National Suicide Research Foundation (2011) 
National Registry of Deliberate Self Harm  
annual report 2010. Cork: National Suicide 
Research Foundation.  
www.drugsandalcohol.ie/15674
National Poisons Information Centre 
(NPIC) 2010 report
According to its annual report,1 NPIC received 
11,589 enquiries in 2010, a decrease of 1.6% from 
2009. Of these, 1,904 were dealt with by the UK 
National Poisons Information Service and are not 
included in the analysis presented in this report.  
Of the 9,685 calls answered by NPIC, 9,330 (96.3%) 
were about human toxicology. The remaining calls 
concerned poisoning in animals (0.7%) and non-
emergency requests for information (2.9%). 
The most frequent enquiries were from general 
practitioners/primary care (38.2%), hospitals (33.2%) 
and members of the public (22.9%). The other 
sources of enquiries were community pharmacists, 
carers, vets, industry/manufacturers, schools, 
emergency services, media and  
government agencies. 
Half of the enquiries about cases of poisoning in 
humans concerned children under 10 years of age, 
and males outnumbered females in this age group. 
There were 2,744 (29.4%) enquiries relating to 
adults (aged 20 years or over) with a predominance 
of females in this age group.
The main agents involved in these cases were drugs 
(pharmaceuticals and drugs of abuse), industrial 
chemicals and household products. The majority 
(93.4%) of all human poisoning incidents occurred in 
the home or in a domestic setting.
More than half (59.6%) of the human cases were 
suspected accidental poisonings, 25.1% were 
intentional poisoning or recreational abuse, 12.2% 
were therapeutic errors, and 3.2% had another or 
unknown intent.
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The enquiries about human toxicology involved 15,164 
agents, mainly drugs, industrial chemicals and household 
products. The most common enquiry concerned substances 
containing paracetamol (1,302). The second most common 
agent was ibuprofen (454). Only a small proportion of cases 
(361, 3.9%) were followed up. Although most recovered 
completely, 24 cases suffered adverse effects, a further 
12 cases died, and the outcome of 34 cases could not be 
determined. One of these fatalities may not have been 
caused by poisoning (post mortem examination to be 
carried out); the others were all cases of deliberate self-
poisoning or drug/substance misuse.
In a section headed ‘Toxicovigilance’, the report includes  
the following: 
In June 2010 the NPIC informed the HSE Department 
of Public Health of significant adverse effects 
associated with a recreational drug called Whack, 
which was being sold in head shops. The HSE 
subsequently issued a warning to the general public 
about the drug. Between the 30th May and 16th 
June 2010 the centre was contacted about 49 
patients who had suffered adverse effects after taking 
Whack. They presented with sympathomimetic 
features of tachycardia and hypertension, as well 
as agitation and severe psychotic reactions with 
delusions of parasitosis and hallucinations, persisting 
for up to 5 days. The Forensic Science Laboratory has 
since analysed this product and found it to contain 
two active ingredients. The first, fluorotropacocaine, 
is a drug of lower potency than the parent 
compound cocaine. The second compound was 
tentatively identified as desoxypipradrol (there 
is no current external reference standard so a 
best library match was used). This is an analogue 
of pipradrol, which is a central nervous system 
stimulant developed in the 1950s. It is likely that the 
severe, long-acting effects associated with Whack are 
due to this agent, as pipradrol has been previously 
associated with psychotic reactions and insomnia. 
(pp. 5–6)
(Mairea Nelson)
1. National Poisons Information Centre of Ireland (2011) 
Annual report 2010. Dublin: Poisons Information Centre 
of Ireland. www.drugsandalcohol.ie/15785
Annual review of the Tallaght 
Rehabilitation Project
The Tallaght Rehabilitation Project (TRP) is a 
community-based rehabilitation day programme 
for people with drug or alcohol addiction who are 
currently drug or alcohol free or who are stable on 
methadone. The annual review for 2010 is now 
available on the TRP website.1
There are 17 places on the day therapeutic 
programme, which runs alongside family support 
activities, aftercare and outreach. During 2010, 
57 people were referred to the day programme, 
of whom 17 were given a place, 20 were referred 
on to other services and six were awaiting 
assessment. Some of the main activities of the 
programme were: key working (433 hours); 
relapse prevention/addiction awareness (254 
hours); therapeutic group process (246 hours); 
and ‘move on’ module (95 hours).
Several participants completed the move on 
module, which provides job-seeking skills 
alongside relapse prevention. In 2010, the 
aftercare service, through a service level 
agreement, was included in the module to further 
improve the successful transition from TRP. 
The Community Employment (CE) scheme in TRP 
had a very successful year in 2010. Currently all 
those on the day programme have a ring-fenced 
position, while a further 10 people are employed 
on the CE scheme to support the activities of the 
project. Five of the day programme participants 
are now in employment (either full-time or CE) 
and two are in full-time third-level education. 
One CE staff member has returned to full-time 
employment and another is now a third-level 
student working part time. 
In order to provide a holistic service to the people 
attending, other services are provided, including: 
family intervention, a play therapist, outreach and 
a partnership with Dublin Rape Crisis Centre.
The Tallaght Wide Aftercare service (TWA) 
expanded its services to five evenings a week in 
2010 and employed a second project worker. In 
2010, 46 people were referred to this service, of 
whom eight were referred on, 24 accessed the 
services regularly, and 14 disengaged. Activities 
undertaken included: social (485 hours); key 
working (175 hours); peer support group (74 
hours); and stress management (70 hours).
The report notes that, despite the 10% reduction 
in funding, TRP has been able to maintain its 
standards and level of staff, but warns that any 
more cuts will inevitably have a negative effect  
on the project’s ability to provide the same level 
of service.
(Suzi Lyons)
1. Tallaght Rehabilitation Project (2011)  
Annual review 2010. Dublin: Tallaght 
Rehabilitation Project.  
http://www.drugsandalcohol.ie/15696
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From Drugnet Europe 
Survey results: youth attitudes to drugs
Cited from article by Maurice Galla, DG Justice, European 
Commission, in Drugnet Europe, No. 75, July–September 2011
The European Commission published on 11 July the results 
of its fourth survey exploring Youth attitudes on drugs.1 This 
‘Flash Eurobarometer’ is based on telephone interviews 
conducted in May 2011 with over 12,000 randomly selected 
young people (aged 15–24) in all 27 EU Member States. It 
builds on three earlier Eurobarometer surveys carried out in 
2002, 2004 and 2008.
Among the issues covered by the survey are: perceptions 
on the health risks of drug use; attitudes to banning or 
regulating substances; views on the availability of drugs; and 
opinions on the effectiveness of policies. For the first time, 
questions were included on new psychoactive substances 
(‘legal highs’).
On average, around 5 % of the young respondents said 
that they had used ‘legal highs’, with Ireland (16%), Latvia 
(9%), Poland (9 %) and the UK (8%) reporting higher rates 
and Italy, Malta and Finland (all around 1%) reporting lower 
rates. These substances were mainly obtained through 
friends (54%), at parties or in clubs (37%), in specialised 
shops (33%) or over the Internet (7%).
…[W]hen asked how they had been informed about drugs 
issues in the past year, the Internet came in third position 
(39%), behind media campaigns (46%) and school 
prevention programmes (41%). However, figures show that 
the Internet has become a more significant drug-related 
information source than in 2008.
In terms of drug control and regulation, the majority of 
respondents (59%) still support cannabis prohibition, but 
this number has declined from 67% since 2008. Regarding 
new psychoactive substances, respondents indicated that 
these should be banned only if they pose a risk to health 
(47%) or be regulated in similar ways to alcohol or tobacco 
(15%). Around one third of respondents (34%) felt that 
these substances should be banned under  
any circumstances.
Released on the same day was a European Commission 
assessment of the EU’s mechanism for addressing new 
psychoactive substances entering the European market.2  
The EMCDDA contributed to this report.
1. http://ec.europa.eu/public_opinion/flash/fl_330_en.pdf
2. http://ec.europa.eu/justice/anti-drugs/document/index_ 
 en.htm
Forum on new drugs — reflections and conclusions
Cited from article by Charlie Lloyd, University of York, and Ana 
Gallegos, EMCDD, in Drugnet Europe, No. 75,  
July–September 2011
The first international multidisciplinary forum on new drugs, 
organised by the EMCDDA in Lisbon from 11–12 May, 
brought together experts from a wide range of disciplines to 
discuss what might be described as a paradigm shift in our 
understanding of ‘the drug problem’.
Delegates came from all over the world to discuss how a 
broad range of new drugs – e.g. mephedrone, BZP and 
synthetic cannabinoids – had begun to be used in their 
countries and how policies had been developed in response. 
… [T]here was a strong impression of commonality. This was 
a global phenomenon, driven by the Internet, with striking 
similarities across the world in the names and packaging 
associated with these substances.
Another overriding impression from participants’ accounts 
was one of dynamism: as one new drug and its use 
subsided, another unrecognised substance emerged to 
replace it. While legal controls appeared to work in terms of 
suppressing production and use, by the time one of these 
drugs was on the legal schedule, clandestine chemists and 
producers had already moved on to producing alternative 
uncontrolled substances. …
Potential solutions discussed at the forum included: public 
health warnings in response to suspected dangers; working 
with the media to publicise harms; introducing general 
legislation that covered whole groups of substances; and 
using laws relating to medicines or consumer protection to 
put the legal onus of product safety on the producer. …
Perhaps with better foresight, experts could identify 
substances likely to become the new drugs of the future. 
The need to recognise potential problems more quickly 
was also underlined. Methods to identify new waves of use 
as they broke, rather than after the event, could include: 
monitoring Internet chatrooms; testing wastewater; and 
using information from hospital emergency departments 
and poison centres. 
Drugnet Europe is the quarterly newsletter of the 
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA). Drugs in focus is a series of 
policy briefings published by the EMCDDA.  
Both publications are available at  
www.emcdda.europa.eu
If you would like a hard copy of the current or 
future issues of either publication, please contact: 
Health Research Board, Knockmaun House, 42–47 
Lower Mount Street, Dublin 2.  
Tel: 01 2345 148; Email: drugnet@hrb.ie
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In brief 
In February of this year In brief reported on the work of the Latin 
American Commission on Drugs and Democracy and the Inter-
American Dialogue on rethinking US drug policy (see Drugnet Ireland 
Issue 37). It also noted that a Global Commission on Drug Policy  
had been established to review the assumptions, effectiveness and 
consequences of the ‘war on drugs’ approach. 
In June 2011 the Global Commission on Drug Policy published 
its report. The report sets out the following ‘key principles and 
recommendations’:
•	 End the criminalisation, marginalisation and stigmatisation 
of people who use drugs but who do not harm others. 
Challenge rather than reinforce common misconceptions 
about drug markets, drug use and drug dependence. 
•	 Encourage experimentation by governments with models 
of legal regulation of drugs to undermine the power of 
organised crime and safeguard the health and security of 
their citizens. Apply this recommendation especially to 
cannabis, but also experiment in the decriminalisation and 
legal regulation of other substances.
•	 Offer health and treatment services to those in need. Ensure 
that a variety of treatment modalities are available, including 
not just methadone and buprenorphine treatment but also 
heroin-assisted treatment programmes. Implement syringe 
access and other harm reduction measures. Respect the 
human rights of people who use drugs. 
•	 Apply the same principles and policies stated above to people 
involved in the lower ends of illegal drug markets, such as 
couriers and petty sellers. The Commission comments, ‘Many 
are themselves victims of violence and intimidation or are 
drug dependent. Arresting and incarcerating these people 
in recent decades has filled prisons and destroyed lives and 
families without reducing the availability of illicit drugs or the 
power of criminal organisations.’
•	 Invest in activities that can both prevent young people 
from taking drugs in the first place and also prevent those 
who do use drugs from developing more serious problems. 
Eschew simplistic ‘just say no’ messages and ‘zero tolerance’ 
policies in favour of educational efforts grounded in credible 
information and prevention programs that focus on social 
skills and peer influences. The Commission points out that 
the most successful prevention efforts may be those targeted 
at specific at-risk groups.
•	 Focus repressive actions on violent criminal organisations,  
but do so in ways that undermine their power and reach 
while prioritising the reduction of violence and intimidation. 
Law enforcement efforts, according to the Commission, 
should focus not on reducing drug markets per se but on 
reducing their harms to individuals, communities and  
national security.
•	 Begin the transformation of the global drug prohibition 
regime. Replace drug policies and strategies driven by 
ideology and political convenience with fiscally responsible 
policies and strategies grounded in science, health, security 
and human rights – and adopt appropriate criteria for  
their evaluation. 
•	 Break the taboo on debate and reform.  
www.globalcommissionondrugs.org
On 14 June 2011 the Think Tank for Action on Social Change 
(TASC) launched a report on health inequalities in Ireland. Authored 
by TASC Head of Policy Sinéad Pentony and Sara Burke, health 
policy analyst and journalist, Eliminating health inequalities – a 
matter of life and death outlines the interrelationship between 
economic inequality and inequality of health outcomes. At the 
launch, Professor Joe Barry, Chair of the TASC Health Inequalities 
Advisory Group, said: ’This report illustrates how responses to the 
current economic crisis are disproportionately impacting on low-
income and vulnerable groups, to the detriment of their health in 
both the short and the long term. The publication of this report 
is timely, as it coincides with the launch of the Government’s 
consultation on a new public health policy.’ Recommendations  
in the report include:
•	 the establishment of an independent review of health 
inequalities, to report within 12 months; 
•	 an equality statement to be published as part of the annual 
budgetary process, examining the distributional impact of 
proposed taxation and spending measures on all income 
levels and on specific demographic groups; 
•	 taxation to be gradually raised to Western European levels, 
with the increased revenue to be used for higher health and 
education spending; 
•	 increased and targeted investment in early childhood care 
and education; 
•	 implementation of a universal social health insurance model. 
www.tascnet.ie 
In June 2011 The Lancet published an article on the findings of 
a study of psychiatric disorders and mortality among people in 
homeless shelters in Denmark between 1999 and 2009.1 The study 
had found increased rates of psychiatric morbidity (particularly 
substance abuse) and vastly increased mortality rates, but had also 
found that homeless people with mental disorders did not have 
increased mortality compared with homeless people who were not 
mentally ill, although there was a relative increase in people with 
substance abuse. A separate commentary on the findings observed:2 
… any additive risk between mental and physical illness on 
rates of mortality seems to be limited to substance abuse. 
This finding is interesting and might indicate that mentally ill 
homeless people who are not substance abusers have better 
access to health services than do homeless people without 
mental illness, perhaps as a result of specialist services 
introduced after the identification of the high rates of mental 
illness. … Mentally ill people who do not abuse substances 
might also spend less time homeless than do those with 
alcohol and drug problems, and substance abuse might be 
associated with a higher number of risk factors for natural 
and non-natural causes of death. … The findings suggest 
that integrated psychiatric and substance abuse treatment 
is necessary to address inequalities, and further treatment 
trials on the best strategies to treat dual-diagnosis homeless 
patients and homeless young people are needed. Such 
enhanced treatment is likely to confer additional benefits, 
including reduction in violent crime, specific causes of 
mortality including suicide, and victimisation. Services need 
to be integrated and flexible: assertive community treatment 
could offer one approach, possibly with community support. 
(Compiled by Brigid Pike)
1. Nielsen SF, Hjorthøj CR, Erlangsen A and Nordentoft M (25 June 
2011–1 July 2011) ‘Psychiatric disorders and mortality among 
people in homeless shelters in Denmark: a nationwide register-
based cohort study’ in The Lancet, 377(9784): 2205–2214.
2. Geddes JR and Fazel S (25 June 2011–1 July 2011) ‘Comment – 
Extreme health inequalities: mortality in homeless people’ in  
The Lancet, 377(9784): 2156–2157.
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Southern Regional Drugs Task Force 
annual report 2010
The Southern Regional Drugs Task Force (SRDTF) annual 
report for 20101 contains information relating the task force, 
budgets, staffing, treatment outcomes and operational 
issues. The section on treatment outcomes analyses data on 
community-based drugs initiatives (CBDIs) returned to the 
National Drug Treatment Reporting System (NDTRS) in the 
Health Research Board. 
CBDI services were accessed by 505 clients in 2010, 
comprising 202 concerned persons (family members or 
close friends of substance users) and 303 people who sought 
treatment for their own addiction. 
Of the 303 who sought treatment: 
•	 More than one-third (35%) were under the age of 
18, and three-quarters (76%) were under the age of 
25 years. 
•	 The majority (72%) lived with parents or family. 
•	 30.0% were still in school, and an additional 30.0% 
were students. 
•	 Cases were mainly self-referred (29.0%), referred by 
family members (22.1%), court, probation or police 
(18.2%), or social services (8.6%).
•	 The most common main problem substance 
reported by cases presenting for treatment were 
alcohol (46.5%), cannabis (27.1%), opiates (10.6%), 
other substances (including hallucinogenic, non-
benzodiazepine-sedatives, head shop substances, 
and other unspecified medications) (6.6%), and 
benzodiazepines (5.0%). Ecstasy, cocaine, other 
stimulants, and volatile inhalants were also reported, 
but to a lesser extent. 
•	 90.4% were treated; 9.6% of those assessed did 
not commence treatment (4.0% were unsuitable, 
2.6% were referred/transferred to another service for 
treatment, 2.3% did not accept the place offered). 
Of 179 cases discharged from treatment in 2010, 30.3% had 
completed treatment or were transferred to another service 
provider for additional treatment; 42.1% refused further 
sessions or did not return for subsequent appointments; 
20.0% did not wish to attend further sessions as they 
considered themselves to be stable. The client’s condition on 
discharge was classified by service providers as stable if they 
had responded to treatment, and unstable if they had not 
responded. Of the 179 cases analysed, the majority (51.1%) 
were stable; 43.8% had a family member or significant other 
involved in their treatment. 
(Anne Marie Carew)
1. Black C (2011) Southern Regional Drugs Task Force annual 
report 2010. Cork: Southern Regional Drugs Task Force. 
www.drugsandalcohol.ie/15132
RADE (recovery through arts, drama and education) aims to 
engage drug users with the arts and therapeutic supports 
and provide a platform for their artistic expression. 
A special screening of Birthday, the last in a trilogy of short 
films made by RADE, was held in the Irish Film Institute on 
Tuesday, 11 October. Birthday was written by Pom Boyd in 
collaboration with RADE participants. The film challenges 
negative stereotypes of drug users. Michael D Higgins TD 
launched the screening. 
Participants in the RADE programme develop their creative 
potential by working on painting, drawing sculpture, 
film making and creative writing, and can apply these 
skills in other aspects of their lives, such as education and 
employment. Several of those involved in the creative 
programme read from a new collection of their work called 
Frontier Folk before the screening.
Premier screening of RADE film, Birthday
Pom Boyd, Darren Balfe and Jenna Duff at the  
film screening
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On our shelves
Books recently acquired by the National Documentation 
Centre on Drug Use.
 Chilling out: the cultural politics of 
substance consumption, youth and  
drug policy
Shane Blackman
Open University Press (2004) 
reprinted 2010
ISBN: 978-0-335-20072-6
 Controversies in drugs policy  
and practice 
Neil McKeganey
Palgrave Macmillan (2011) 
ISBN: 978-0-230-23595-3   
www.drugsandalcohol.ie/15978
 Legalization of drugs 
Mark D Friedman
Heinemann Library (2011) Hot Topics
ISBN: 978-1-4329-4872-6
www.drugsandalcohol.ie/15980
Journal articles
The following abstracts are cited from recently published 
articles relating to the drugs situation in Ireland.
Risk of drug-related mortality during periods of transition  
in methadone maintenance treatment: A cohort study
Cousins G, Teljeur C, Motterlini N, McCowan C, Dimitrov  
BD and Fahey T 
Journal of Substance Abuse Treatment, 2011; 41(3): 252–60. 
www.drugsandalcohol.ie/15442
This study aims to identify periods of elevated risk of drug-
related mortality during methadone maintenance treatment 
(MMT) in primary care using a cohort of 3,162 Scottish drug 
users between January 1993 and February 2004. Deaths 
occurring during treatment or within three days after last 
methadone prescription expired were considered as cases 
‘on treatment’. Fatalities occurring four days or more after 
leaving treatment were cases ‘off treatment’. Sixty-four 
drug related deaths were identified. The greatest risk of 
drug related death was in the first two weeks of treatment. 
Risk of drug-related death was lower after the first 30 days 
following treatment cessation, relative to the first 30 days off 
treatment. History of psychiatric admission was associated 
with increased risk of drug-related death in treatment. 
Increasing numbers of treatment episodes and urine 
testing were protective. History of psychiatric admission, 
increasing numbers of urine tests, and co-prescriptions 
of benzodiazepines increased the risk of mortality out of 
treatment. The risk of drug-related mortality in MMT is 
elevated during periods of treatment transition, specifically 
treatment initiation and the first 30 days following treatment 
dropout or discharge.
Prevalence, predictors and perinatal outcomes of peri-
conceptional alcohol exposure – retrospective cohort study 
in an urban obstetric population in Ireland
Mullally A, Cleary BJ, Barry J, Fahey T and Murphy DJ 
BMC Pregnancy & Childbirth, 2011; 41(3): 252–260. Epub 
11 April http://www.biomedcentral.com/1471-2393/11/27. 
www.drugsandalcohol.ie/15475
A cohort study of 61,241 women who booked for antenatal 
care and delivered in a large urban maternity hospital 
between 2000 and 2007. Self-reported alcohol consumption 
at the booking visit was categorised as low (0-5 units per 
week), moderate (6-20 units per week) and high (&gt;20 
units per week). 
Of the 81% of women who reported alcohol consumption 
during the peri-conceptional period, 71% reported low 
intake, 9.9% moderate intake and 0.2% high intake. Factors 
associated with moderate alcohol consumption included 
being in employment, Irish nationality, private health care 
and smoking. Factors associated with high consumption 
included maternal age less than 25 years and illicit drug 
use. High consumption was associated with very preterm 
birth (&lt;32 weeks gestation) even after controlling for 
socio-demographic factors. Only three cases of Fetal Alcohol 
Syndrome were recorded (0.05 per 1000 total births), one 
each in the low, moderate and high consumption groups. 
Public health campaigns need to emphasise the importance 
of peri-conceptional health and pre-pregnancy planning. 
Fetal Alcohol Syndrome is likely to be under-reported  
despite the high prevalence of alcohol consumption in  
this population.
Gateway transitions in rural Irish youth: implications for 
culturally appropriate and targeted drug prevention  
Van Hout MC and Ryan R
Journal of Alcohol & Drug Education, 2011; 55(1): 7–14. 
www.drugsandalcohol.ie/15182
In recent times rural areas in Ireland are indicating 
comparable drug availability and prevalence of use to urban 
settings, with the recognition of development of unique 
rural drug subcultures (NACD, 2008). Additionally, there is 
a dearth of research on drug-use initiation and transitions 
among Irish youth, and most particularly outside of the 
urban context. This letter presents snapshot quantitative 
findings from a large scale concurrent mixed method study 
on rural youth substance use in the South East of Ireland. 
It aims to discuss the observed quantitative findings with 
reference to potential implications for the design of culturally 
appropriate and drug specific drug education initiatives in 
rural Ireland.
Commentary on ‘The research translation problem: alcohol 
screening and brief intervention in primary care – real world 
evidence supports theory’
Klimas J, Field CA, Barry J, Bury G, Keenan E, Lyons S et al.  
Drugs: education, prevention and policy, 2011, 24 June;  
Early online.  
www.drugsandalcohol.ie/15393
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The paper by McCormick et al. (2010) provides real-
world examples of best practice for implementing alcohol 
screening and brief intervention (SBI) in primary care. We 
commend the authors for that and also wish to highlight 
the additional challenges involved in implementing SBI 
in primary care among vulnerable populations, especially 
problem drug users. To explore the scientific evidence on 
implementing best practice in SBI for problem alcohol use 
among problem drug users, we conducted a Medline search 
with the following keywords: setting (primary care),target 
behaviour (problem alcohol use), population (problem 
drug users) and implementation strategies (e.g. guidelines, 
barriers or enablers). The majority of papers we identified 
concerned the general adult population and we consider this 
literature in conjunction with that specific to problem drug 
users, where relevant.
Forging a path for abstinence from heroin: a grounded 
theory of detoxification-seeking 
McDonnell A and Van Hout MC  
Grounded Theory Review, 2011; 10(1); 17–41.  
www.drugsandalcohol.ie/15186
Through a classic grounded theory approach, this study 
conceptualises that the main concern of heroin users who 
are seeking detoxification is giving up heroin use, ‘getting 
clean’. Forging a path for abstinence explains how people 
respond to their concern of getting clean from heroin. 
Three sub-processes make up this response; resolution 
(resolving to stop); navigation (deciding how to stop), and 
initiation (stopping use). These sub-processes are carried 
out by heroin users within a context of subjective levels of 
four significant personal resources; dependence knowledge; 
treatment awareness; treatment access, and alliance.  
The nature of the resource context greatly determines 
whether a heroin user seeks detoxification, or not, 
is response to getting clean. The substantive theory 
demonstrates that valuable insights are gained from 
studying heroin users' out-of-treatment experiences of  
trying to become drug free.
Suicide in Ireland: the influence of alcohol and 
unemployment
Walsh BM and Walsh D 
Economic and Social Review, 2011; 42(1): 27–47
www.drugsandalcohol.ie/15042
We model the behaviour of the Irish suicide rate over  
the period 1968–2009 using the unemployment rate  
and the level of alcohol consumption as the principal 
explanatory variables. 
We find that alcohol consumption is a significant influence 
on the suicide rate among younger males. Its influence on 
the female suicide rate is not well-established, although 
there is some evidence that it plays a role in the 15–24 
age group. The unemployment rate is also a significant 
influence on the male suicide rate in the younger age groups 
but evidence of its influence on the female suicide rate is 
lacking. The behaviour of suicide rates among males aged 
55 and over and females aged 25 and over is unaccounted 
for by our model. The findings suggest that higher alcohol 
consumption played a significant role in the very rapid 
increase in suicide mortality among young Irish males 
between the late 1980s and the end of the century. In the 
early twenty first century a combination of falling alcohol 
consumption and low unemployment led to a marked 
reduction in suicide rates. The recent rise in suicide rates 
may be attributed to the sharp rise in unemployment, 
especially among males, but it has been moderated by the 
continuing fall in alcohol consumption. Finally, we discuss 
some policy implications of our findings.
A prospective, randomized, multicenter acceptability and 
safety study of direct buprenorphine / naloxone induction in 
heroin-dependent individuals 
Amass L, Pukelevidiene V, Subata E, Almeida AR, Pieri MC, 
D’Edgidio P et al.
Addiction, 2011, 12 July; Epub ahead of print.
www.drugsandalcohol.ie/15537
This study involved 187 opioid-dependent men and women 
≥15 years of age in 19 sites in 10 European countries from 
March 2008 to December 2009. The primary objective was 
assessment of patient response to direct and indirect BNX 
induction (proportion of patients receiving the scheduled 
16-mg BNX dose on day 3 [i.e. first day post-induction]). 
Secondary assessments included illicit drug use, treatment 
retention and compliance, withdrawal scale scores,  
and safety.
The authors concluded that direct BNX induction was a safe 
and effective strategy for maintenance treatment of opioid 
dependence. Response to high-dose direct BNX induction 
appears to be similar to indirect BPN-to-BNX induction and 
was not associated with reports of intravenous BNX misuse.
Outcome of heroin-dependent adolescents presenting for 
opiate substitution treatment. 
Smyth BP, Fagan J and Kernan K 
Journal of Substance Abuse Treatment, 2011, 20 Sep;  
Epub ahead of print 
http://www.drugsandalcohol.ie/15964
Because the outcome of methadone and buprenorphine 
substitution treatment in adolescents is unclear, we 
completed a retrospective cohort study of 100 consecutive 
heroin-dependent adolescents who sought these treatments 
over an eight-year recruitment period. The participants’ 
average age was 16.6 years, and 54 were female. Half 
of the patient group remained in treatment for over one 
year. Among those still in treatment at 12 months, 39% 
demonstrated abstinence from heroin. The final route of 
departure from the treatment program was via planned 
detox for 22%, dropout for 32%, and imprisonment for 
8%. The remaining 39% were transferred elsewhere for 
ongoing opiate substitution treatment after a median period 
of 23 months of treatment. Males were more likely to exit 
via imprisonment (p b .05), but other outcomes were not 
predicted by gender. There were no deaths during treatment 
among these 100 patients who had a cumulative period 
of 129 person years at risk. Our findings suggest that this 
treatment delivers reductions in heroin use and that one fifth 
of patients will exit treatment following detox completion 
within a one- to two-year time frame.
Recent>publications>(continued)
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(Compiled by Joan Moore – jmoore@hrb.ie)
November 
3–12 November 2011 
Cork Drug Awareness Events 
Venue: Various
Organised by / Contact: Cork City Partnership and Cork 
Local Drugs Task Force 
Email: mmagee@partnershipcork.ie, jdaly@partnershipcork.ie 
Tel: (021) 430 2310
www.corkdrugsinfo.ie
Information: Cork Drug Awareness Events aim to raise 
awareness and signpost information so that communities, 
families and professionals know where to go for assistance or 
information on drug and alcohol services.
This series of citywide and community-based events will 
run over two weeks, with free admission to all except the 
play Cracking Lives (see website for details of all events). The 
conference, Benzodiazepines: An Integrated Response, on 
Wednesday 9 November will highlight consumption and 
problematic use of benzodiazepines in Ireland, and illustrate 
best practice (early booking essential).
3–4 November 2011
Drug Interventions: What Works? National Drugs Conference 
of Ireland 2011 
Venue: Radisson Blu Royal Hotel Dublin 8
Organised by / Contact: Conference Steering Group /Irish 
Needle Exchange Forum 
Email: tim@inef.ie
http://inef.ie
Information: This year’s conference will build on the success 
of the 2010 conference, bringing together a range of 
national and international speakers from across the spectrum 
of addiction research, service provision and policy. The 
conference is sponsored by the HSE’s National Addiction 
Training Programme (NATP) which worked with the 
Conference Steering Group, (representatives from the Irish 
Needle Exchange Forum, Ana Liffey Drug Project, Coolmine 
Therapeutic Community and the Irish Association of Alcohol 
and Addiction Counsellors).
Plenary speakers:
Damon Barrett – Human rights based approach to  
drug policy
Johnny Connolly – Understanding the drugs market
Brian Dalton – Stimulants and contingency management:  
a provider perspective
Dr Paolo Deluca – How the Internet and social media are 
driving the legal highs phenomenon: findings from the  
ReDNet project
Dr Joao Goulao – Drug policies in Portugal: was 
decriminalisation helpful?
Jelena Ivanovic – Drugs.ie - your new online community  
of services
Dr Thomas McLellan – Re-thinking substance abuse: 
transitioning our policies and practices
Greg Purvis – If you build it they will come but if you don’t 
sustain it they will leave. Implementing and sustaining 
evidence- based practice
Dr Jenny Scott – The role of the pharmacist within a 
pharmacy needle exchange
Dr Andrew Tatarsky – Substance misuse is not just a brain 
disease: the personal and social meanings of substance use and 
the critical role of integrative harm reduction psychotherapy
Martin Woods – Drug killings in Mexico, money laundering in 
London, it’s all connected.
10–12 November 2011
The 1st International NEAR conference: (Neuroscience and 
Evidence based practices for Addiction Recovery) 
Venue: Ritz Carlton Hotel, Powerscourt, Co Wicklow
Organised by / Contact: Toranfield House and Southworth 
& Associates
Email: jackie.l@toranfieldhouse.com 
www.nearconference.com
Information: This is Ireland’s first international conference 
and exhibition on behavioural health including addiction 
disorders. Delegates will be introduced to new concepts and 
ideas from international and local speakers and will leave the 
three-day conference with an understanding of what the 
latest neurobiological research illustrates about addiction 
and an understanding of the latest evidence-based practices 
associated with treatment. Alastair Campbell is our guest 
speaker, and he will be talking about his own behavioural 
health issues and how he overcame them, while working in 
his hugely stressful career as Tony Blair’s right-hand man. 
Other speakers include Paddy Creedon, Anne Twohig-Wall, 
Dr Bobby Smyth, Ewa Woydyllo Osiatynska, Rory O’Connor, 
Dr Susan Campling, Dr Joe Barry, Grace Ball, Dr Colin 
O’Gara, Rolande Anderson and Stephen Rowen.
15 November 2011
Alcohol – Where’s the Harm? Exploring the public face and 
hidden harm of alcohol-related crime in Ireland
Venue: Royal College of Physicians, Kildare Street, Dublin 2
Organised by / Contact: Alcohol Action Ireland
Email: info@alcoholactionireland.ie 
Tel: 01 878 0610
www.alcoholireland.ie
Information: Alcohol Action Ireland’s conference will 
examine the relationship between alcohol and ‘public’ 
crime in Ireland. It will also seek to explore ‘hidden’ crime 
– sexual violence and domestic violence. The conference is 
free but we would ask participants who can do so to make a 
donation to Alcohol Action Ireland via our website in order 
to help us cover our costs.
Conference will be opened by Minister of State Róisín 
Shortall. Confirmed speakers include:
•	 International research expert on alcohol-related harm 
Dr Ann Hope
•	 DIT lecturer in economics Sean Byrne, author of the 
HSE report on alcohol-related costs to society
•	 Director of the Garda Juvenile Diversion Progamme, 
Superintendent Colette Quinn
•	 HSE South Health Promotion Officer,  
Sandra Coughlan
•	 Rape Crisis Network of Ireland, Director of Advocacy, 
Dr Cliona Sadlier
•	 SAFE Ireland Director, Sharon O’Halloran 
Upcoming events
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Drugnet Ireland is 
published by:
Health Research Board 
Knockmaun House 
42–47 Lower Mount Street 
Dublin 2 
Tel: + 353 1 2345 148 
Email: drugnet@hrb.ie
Managing editor:  
Brian Galvin 
Editor: Joan Moore
•	 Christine Toft of the Alcohol Concern 
(UK) Embrace project
13–17 November 2011
54th ICAA Conference: The place of recovery  
in treatment: Strength through Diversity –  
An Inclusive Approach
Venue: London, England 
Organised by / Contact: International Council 
on Alcohol and Addictions (ICAA)
Email: peterorstad@aol.com 
www.icaa.ch
Information: Endorsed by the Medical Council 
on Alcohol and located in the British Medical 
Association Conference Centre, the conference 
will be addressed by leading international figures 
from the field of addictive behaviours. Topics 
addressed will include national and international 
policy, prevention programmes, findings from 
psychopharmacology, assessment,  
harm reduction, accessing services and 
addiction medicine. 
December 
1 December 2011
Growing Up in Ireland Annual Conference 2011
Venue: D4 Berkeley Hotel, Lansdowne Road
Organised by / Contact: ESRI / Claire Delaney
Tel: 01 863 2053
Email: guiconference2011@esri.ie
www.growingup.ie  
Information: The third annual research 
conference of Growing Up in Ireland – the 
National Longitudinal Study of Children will 
be opened by Frances Fitzgerald TD, Minister 
for Children and Youth Affairs, who will launch 
some key findings from the recently completed 
Infant Cohort (at 3 years) as well as some of the 
first longitudinal findings from the study. 
The keynote speaker is Professor Edward 
Melhuish, Professor of Human Development 
at Birkbeck, University of London, an 
internationally recognised expert in the study 
of child development and childcare and has 
extensive experience with longitudinal studies. 
A total of 24 papers will be presented by 
researchers from a wide range of third-level 
and research institutions. These will be based 
on data from Growing Up in Ireland’s Child and 
Infant Cohorts and will focus on a range of 
topics including health, parenting, education 
and childcare. 
Early booking is encouraged and bookings 
should only be made on the official registration 
form (see our website). 
5–7 December 2011
The Global Addiction Conference
Venue: Universidade Catolica, Lisbon, Portugal
Organised by / Contact: Cortex Congress Ltd
Email: peterorstad@aol.com
www.globaladdiction.org
Information: Global Addiction is a new 
electronic portal for educational services in 
the area of addiction medicine. The Global 
Addiction Conference has grown out of the 
EAAT (European Association of Addiction 
Therapies) conferences, the last of which 
was in 2009. Global Addiction aims to cover 
all topics relating to the understanding and 
treatment of addictive disorders. This includes 
pre-clinical, neurophysiological mechanisms 
through diagnostic and treatment strategies to 
societal guidelines and health economics. This 
conference brings speakers from across  
the globe and from the whole spectrum of topic 
areas pertinent to addiction. The EMCDDA 
will participate in a session on ‘Innovation and 
quality’. Cross fertilisation of ideas and best 
practice will be a fundamental part of  
the programme.
8–9 December 2011
European Society for Prevention Research:  
2nd International Conference and  
Members’ Meeting
Venue: Lisbon, Portugal
Organised by / Contact: EUSPR /  
European Monitoring Centre for Drugs  
and Drug Addiction
Email: barbara.zunino@oed.piemonte.it
www.euspr.org
Information: The title of this conference is 
‘Synergy in prevention and health promotion: 
individual, community, and environmental 
approaches’. While there is sufficient knowledge 
about the effects of some health education 
programmes and school-based interventions, 
our understanding of how interventions brought 
at the level of the environment might work 
is poor. In order to fill this gap, the scientific 
evaluation of environmental interventions, as 
well as of complex community interventions 
should become a priority. Keynote speakers 
will explore environmental approaches to 
prevention, comparing with individual and 
community level approaches. Also covered 
will be pathways to prevention, and the 
methodological challenges in undertaking 
prevention research at these different levels. 
Upcoming>events>(continued)
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